HK1220602B

HK1220602B - Bioabsorbable biomedical implants

Info

Publication number: HK1220602B
Application number: HK16108740.8A
Authority: HK
Inventors: B. Mcclain James; Douglas Taylor Charles; Steven Burgermeister Robert
Original assignee: Micell Medtech Inc.
Priority date: 2013-03-12
Filing date: 2014-03-12
Publication date: 2024-09-27

Description

BACKGROUND

The present disclosure relates to bioabsorbable stents made of polymeric materials and methods of manufacturing the bioabsorbable stents.

US 2010/241220 discloses a stent having a plurality of stent struts, which is provided with a coating comprising a macrolide immunosuppressive drug in crystalline form, e.g. rapamycin, and a resorbable polymer. The coating is formed by depositing the drug and coating polymer in dry powder form. The stent may be formed of any suitable material including stable or biodegradable polymers, metals and inorganic materials.

SUMMARY OF THE DISCLOSURE

The invention is as defined in claims 1 to 9. Any "embodiment" or "example" which is disclosed in the description but is not covered by the claims should be considered as presented for illustrative purpose only.

According to one aspect of the present invention, a biomedical implant is disclosed as including a tubular scaffold comprising a plurality of interconnected bioabsorbable polymer struts. The interconnected polymer struts defines a plurality of deformable cells, wherein the tubular scaffold includes polymer chains that are circumferentially aligned along a center axis of the tubular scaffold, so that the tubular scaffold has an average axial elastic modulus along a center axis of the tubular scaffold and an average circumferential elastic modulus orthogonal to the center axis of the tubular scaffold, the average circumferential elastic modulus being greater than the average axial elastic modulus. A pharmaceutical agent is incorporated to the tubular scaffold, wherein at least a portion of the tubular scaffold is covered with a coating comprising the pharmaceutical agent which is a macrolide immunosuppressant in crystalline form and a bioabsorbable coating polymer. The polymer struts have an average strut thickness of no more than 120 µm.

In one embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg. 1 mmHG corresponds to 133.322 Pa; 1 ATM corresponds to 101.325 kPa. In another embodiment, the tubular scaffold maintains at least 80% of its nominal luminal cross sectional area under a pressure load of 50mmHg.

In one embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg upon 3 months of exposure to saline in vitro. In another embodiment, the tubular scaffold maintains at least 50% of its deployed luminal cross sectional area under a pressure load of 50mmHg upon 3 months in vivo.

In one embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg upon 6 months of exposure to saline in vitro. In another embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg upon 6 months in vivo.

In one embodiment, at least 80% of the polymer struts are bioabsorbed within 2 years after deployment in vivo. In another embodiment, at least 80% of the polymer struts are bioabsorbed within 1year after deployment in vivo.

In one embodiment, the polymer struts have an average strut thickness of no more than 100 µm. In another embodiment, the polymer struts have an average strut thickness of no more than 80 µm.

In one embodiment, the polymer struts have an average deformation angle of at least 60 degrees. In another embodiment, the polymer struts have an average deformation angle of at least 45 degrees.

In one embodiment, the polymer struts comprises a gel-spun polymer material. In a refinement, the polymer struts are not structurally reinforced with a metal material. In a further refinement, the gelspun polymer material is selected from the group consisting of polylactides (PLA); poly(lactide-coglycolide) (PLGA); polyanhydrides; polyorthoesters; poly(N -(2-hydroxypropyl) methacrylamide); poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); poly(d-lactide) (DPLA); polyglycolide (PGA); poly(dioxanone) (PDO); poly(glycolide-co-trimethylene carbonate) (PGA-TMC); poly(l-lactide-coglycolide) (PGA-LPLA); poly( dl-lactide-co-glycolide) (PGA-DLPLA); poly(l-lactide-co-dl-lactide) (LPLA-DLPLA); poly(glycolide-co-trimethylene carbonate-co-dioxanone) (PDO-PGA-TMC), poly(lactic acid-co-caprolactone) (PLACL), and mixtures or co-polymers thereof.

In one refinement, the gel-spun polymer material is PLGA. In a further refinement, the PLGA has a ratio of lactic acid monomer to glycolic acid monomer ranging from 72:28 to 78:22. In another further refinement, the PLGA has a ratio of lactic acid monomer to glycolic acid monomer ranging from 62:38 to 68:32. In another further refinement, the PLGA has a ratio of lactic acid monomer to glycolic acid monomer ranging from 47:53 to 53:47. In another further refinement, the PLGA has a weight average molecular weight of about 8,000 Dalton to about 12,000 Dalton. In another further refinement, the PLGA has a weight average molecular weight of about 12,000 Dalton to about 16,000 Dalton. In another further refinement, the PLGA has a weight average molecular weight of up to about 90,000 Dalton. In another refinement, the gelspun polymer material is PLA or LPLA. In another refinement, the gel-spun polymer material is PGA. In some embodiment, the gel spun polymer material (e.g. PLGA, LPLA, PLA, and PGA) has a weight average molecular weight of at least 90,000 Dalton, and optionally at least 100,000 Dalton.

In one embodiment, the polymer struts comprises a liquid crystalline polymer material. In a refinement, the liquid crystalline polymer material is drawn from a liquid crystalline melt or solution. In another refinement, the polymer struts are not structurally reinforced with a metal material. In a further refinement, the liquid crystalline polymer material is selected from the group consisting of polylactides (PLA); poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); poly(d-lactide) (DPLA); polyglycolide (PGA); poly( dioxanone) (PDO); poly(l-lactide-co-glycolide) (PGA-LPLA); poly(l-lactide-co-dl-lactide) (LPLA-DLPLA), poly(lactic acid-co-caprolactone) (PLACL), and mixtures or co-polymers thereof.

In another refinement, the liquid crystalline polymer material has a crystallinity of at least 30%. In another refinement, the liquid crystalline polymer material has a crystallinity of at least 35%. In another refinement, the liquid crystalline polymer material has a crystallinity of at least 40%.

In another refinement, the liquid crystalline polymer material is PLA or LPLA. In another refinement, the liquid crystalline polymer material is PGA. In some embodiment, the liquid crystalline polymer material (e.g. LPLA, PLA, PGA) has a weight average molecular weight of at least 90,000 Dalton, and optionally at least 100,000 Dalton.

In one embodiment, the polymer struts include a polymer material selected from the group consisting of polycarboxylic acids, cellulosic polymers, proteins, polypeptides, polyvinylpyrrolidone, maleic anhydride polymers, polyamides, polyvinyl alcohols, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters, aliphatic polyesters, polyurethanes, polystyrenes, copolymers, silicones, silicone containing polymers, polyalkyl siloxanes, polyorthoesters, polyanhydrides, copolymers of vinyl monomers, polycarbonates, polyethylenes, polypropytenes, polylactic acids, polylactides, polyglycolic acids, polyglycolides, polylactide-co-glycolides, polycaprolactones, poly( e-caprolactone )s, polyhydroxybutyrate valerates, polyacrylamides, polyethers, polyurethane dispersions, polyacrylates, acrylic latex dispersions, polyacrylic acid, polyalkyl methacrylates, polyalkylene-co-vinyl acetates, polyalkylenes, aliphatic polycarbonates polyhydroxyalkanoates, polytetrahalooalkylenes, poly(phosphasones ), polytetrahalooalkylenes, poly(phosphasones ), and mixtures, combinations, and copolymers thereof.

In one embodiment, the tubular scaffold is expandable from an undeployed diameter to a nominal diameter without affecting the structural integrity of the tubular scaffold. In a refinement, the tubular scaffold is further expandable from the nominal diameter to an over-deployed diameter without affecting the structural integrity of the tubular scaffold. In a further refinement, the over-deployed diameter is about 1.0 mm greater than the nominal diameter. In another further refinement, the overdeployed diameter is about 0.5 mm greater than the nominal diameter.

In one refinement, the tubular scaffold is expandable by an inflatable balloon positioned within the tubular scaffold. In a further refinement, the tubular scaffold has a nominal diameter of 2.25 mm at nominal balloon pressure. In another further refinement, the tubular scaffold has a nominal diameter of 2.5 mm at nominal balloon pressure. In another further refinement, the tubular scaffold has a nominal diameter of 3.0 mm at nominal balloon pressure. In another further refinement, the tubular scaffold has a nominal diameter of 3.5 mm at nominal balloon pressure. In another further refinement, the tubular scaffold has a nominal diameter of 4.0 mm at nominal balloon pressure. In another further refinement, the tubular scaffold has a nominal diameter of 4.5 mm at nominal balloon pressure.

In one refinement, the polymer struts comprise a shape-memory polymer and wherein tubular scaffold is self-expandable. In a further refinement, the tubular scaffold is self-expandable upon change in temperature. In another further refinement, the tubular scaffold is self-expandable upon change in crystallinity of the shape-memory polymer.

In one embodiment, the tubular scaffold is formed from a plurality of sinusoidal polymer fibers. In a refinement, the sinusoidal polymer fibers are interconnected at a plurality of connecting points.

In one embodiment, the tubular scaffold is formed from a single polymer fiber. In a refinement, the single polymer fiber comprises a plurality of sinusoidal sections interconnected at a plurality of connecting points.

According to the claimed invention, the biomedical implant further includes a pharmaceutical agent incorporated to the tubular scaffold. This pharmaceutical agent is a macrolide immunosuppressant in crystalline form. In a refinement, the macrolide immunosuppressant is rapamycin or a derivative, a prodrug, a hydrate, an ester, a salt, or a polymorph thereof. In another further refinement, the macrolide immunosuppressant is selected from the group consisting of rapamycin, 40-0-(2-Hydroxyethyl)rapamycin, (everolimus), 40-0-Benzyl-rapamycin, 40-0-( 4'-Hydroxymethyl)benzylrapamycin, 40-0-[ 4 '-( 1 ,2-Dihydroxyethyl) ]benzyl-rapamycin, 40-0-Allyl-rapamycin, 40-0-[3 '-(2,2-Dimethyl-1 ,3-dioxolan-4(S)-yl)-prop-2' -en-1 '-yl] -rapamycin, (2':E,4'S)-40-0-( 4',5'-Dihydroxypent-2'-en-1 '-yl)-rapamycin, 40-0-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-0-(3-Hydroxy)propylrapamycin, 40-0-( 6-Hydroxy)hexyl-rapamycin, 40-0-[2-(2-Hydroxy)ethoxy] ethyl-rapamycin, 40-0-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-0-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-0-(2-Acetoxy)ethyl-rapamycin, 40-0-(2-Nicotinoyloxy)ethyl-rapamycin, 40-0-[2-(NMorpholino)acetoxy] ethyl-rapamycin, 40-0-(2-N-Imidazolylacetoxy )ethyl-rapamycin, 40-0-[2-(NMethyl-N' -piperazinyl)acetoxy] ethyl-rapamycin, 39-0-Desmethyl-39, 40-0, 0-ethylene-rapamycin, (26R )-26-Dihydro-40-0-(2-hydroxy)ethyl-rapamycin, 28-0-Methyl-rapamycin, 40-0-(2-Aminoethyl)rapamycin, 40-0-(2-Acetaminoethyl)-rapamycin, 40-0-(2-Nicotinamidoethyl)-rapamycin, 40-0-(2-(NMethyl-imidazo-2'-ylcarbethoxamido)ethyl)-rapamycin, 40-0-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-0-(2-Tolylsulfonamidoethyl)-rapamycin, 40-0-[2-( 4',5'-Dicarboethoxy-1 ',2',3'-triazol-1 '-yl)-ethyl]rapamycin, 4 2-Epi-( tetrazolyl)rapamycin (tacrolimus ), and 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin. In one refinement, the pharmaceutical agent is rapamycin.

According to the claimed invention, at least a portion of the tubular scaffold is covered with a coating comprising the pharmaceutical agent. The coating further comprises a coating polymer. In a further refinement, at least 90% of the surface area of the pharmaceutical agent is encapsulated in the coating polymer. According to the claimed invention, the coating polymer comprises a bioabsorbable polymer. In a further refinement, the bioabsorbable polymer is selected from the group consisting of polylactides (PLA); poly(lactide-co-glycolide) (PLGA); polyanhydrides; polyorthoesters; poly(N-(2- hydroxypropyl)methacrylamide); poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); polyglycolide (PGA); poly( dioxanone) (PDO); poly(glycolide-co-trimethylene carbonate) (PGA-TMC); poly(l-lactide-co-glycolide) (PGA-LPLA); poly( dl-lactide-co-glycolide) (PGA-DLPLA); poly(l-lactide-co-dl-lactide) (LPLA-DLPLA); poly(glycolide-co-trimethylene carbonate-co-dioxanone) (PDO-PGA-TMC), polyarginine, and mixtures or co-polymers thereof. In a further refinement, the biodegradable polymer is selected from the group consisting of PLGA, polyarginine, and mixtures thereof.

In one embodiment, the biomedical implant is a vascular stent. In another embodiment, the biomedical implant is a coronary artery stent. In another embodiment, the biomedical implant is a peripheral artery stent. In another embodiment, the biomedical implant is a non-vascular stent. In a refinement, the non-vascular stent is selected from esophageal stent, biliary stent, duodenal stent, colonic stent, and pancreatic stent.

According to another aspect of the present disclosure, which does not form part of the claimed invention, a method of forming a gel-spun polyester fiber is provided. The method includes the steps of forming a gel composition comprising the polyester and a solvent; extruding the gel composition through one or more orifices into a stream of drying air; and allowing the solvent to evaporate in the drying air to form the polyester fiber. In a refinement, the method further includes the step of drawing the extruded polymer.

In one embodiment, the method further includes the step of cooling the polyester fiber in a liquid bath.

In one embodiment, the gel composition is extruded through a spinneret.

In one embodiment, the polyester is selected from the group consisting ofpolylactides (PLA); poly(lactide-co-glycolide) (PLGA); polyanhydrides; polyorthoesters; poly(N-(2-hydroxypropyl) methacrylamide); poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); poly(d-lactide) (DPLA);polyglycolide (PGA); poly( dioxanone) (PDO); poly(glycolide-co-trimethylene carbonate) (PGA-TMC);poly(l-lactide-co-glycolide) (PGA-LPLA); poly( dl-lactide-co-glycolide) (PGA-DLPLA); poly(l-lactideco-dl-lactide) (LPLA-DLPLA); poly(glycolide-co-trimethylene carbonate-co-dioxanone) (PDO-PGATMC),poly(lactic acid-co-caprolactone) (PLACL), and mixtures or co-polymers thereof. In a refinement, the polyester is PLGA. In another refinement, the polyester is PLA or LPLA.

According to another aspect of the present disclsoure, which does not form part of the claimed invention, a method of forming a liquid crystalline polyester fiber is provided. The method includes the steps of forming a liquid crystalline composition comprising the polyester; and extruding the liquid crystalline composition to form the polyester fiber.

In one embodiment, the polyester is in a melted state and wherein the method further comprises cooling the polyester fiber.

In one embodiment, the liquid crystalline composition further comprises a solvent and wherein the method further comprises allowing the solvent to evaporate.

In one embodiment, the polyester is selected from the group consisting ofpolylactides (PLA);poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); poly(d-lactide) (DPLA); polyglycolide (PGA);poly( dioxanone) (PDO); poly(l-lactide-co-glycolide) (PGA-LPLA); poly(l-lactide-co-dl-lactide) (LPLADLPLA),poly(lactic acid-co-caprolactone) (PLACL), and mixtures or co-polymers thereof. In a refinement, the polyester is PLA. In another refinement, the polyester is LPLA. In another refinement, the polyester is PGA.

In some embodiments of the disclosed method of forming a gel-spun polyester fiber and/ or forming a liquid crystalline polyester fiber, the polyester fiber has anisotropic elastic modulus. In a refinement, the polyester fiber comprises substantially aligned polymer chains.

According to another aspect of the present disclosure, which does not form part of the claimed invention, a method of forming a biomedical implant is disclosed. The method includes the steps of forming one or more polymer fibers comprising longitudinally aligned polymer chains; and interconnecting the polymer fibers to form a tubular scaffold, the tubular scaffold comprising a plurality of interconnected polymer struts to define a plurality of deformable cells.

In one embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg. In another embodiment, the tubular scaffold maintains at least 80% of its nominal luminal cross sectional area under a pressure load of 50mmHg.

In one embodiment, the tubular scaffold is form from a plurality of sinusoidal polymer fibers. In a refinement, the sinusoidal polymer fibers are interconnected at a plurality of connecting points.

In one embodiment, the one or more polymer fibers comprise gel-spun polyester. In a refinement, the polyester is selected from the group consisting ofpolylactides (PLA); poly(lactide-coglycolide) (PLGA); polyanhydrides; polyorthoesters; poly(N -(2- hydroxypropyl) methacrylamide ); poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); poly(d-lactide) (DPLA); polyglycolide (PGA); poly( dioxanone) (PDO); poly(glycolide-co-trimethylene carbonate) (PGA-TMC); poly(l-lactide-coglycolide) (PGA-LPLA); poly( dl-lactide-co-glycolide) (PGA-DLPLA); poly(l-lactide-co-dl-lactide) (LPLA-DLPLA); poly(glycolide-co-trimethylene carbonate-co-dioxanone) (PDO-PGA-TMC), poly(lactic acid-co-caprolactone) (PLACL), and mixtures or co-polymers thereof. In a further refinement, the polyester is PLGA. In another further refinement, the polyester is PLA or LPLA.

In one embodiment, the one or more polymer fibers comprise liquid crystalline polyester. In a refinement, the polyester is selected from the group consisting ofpolylactides (PLA); poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); poly(d-lactide) (DPLA); polyglycolide (PGA); poly(dioxanone) (PDO); poly(l-lactide-co-glycolide) (PGA-LPLA); poly(l-lactide-co-dl-lactide) (LPLA-DLPLA), poly(lactic acid-co-caprolactone) (PLACL), and mixtures or co-polymers thereof. In a further refinement, the polyester is PLA. In another further refinement, the polyester is LPLA. In another further refinement, the polyester is PGA.

In one embodiment, the one or more polymer fibers have anisotropic elastic modulus.

In one embodiment, the method further includes the step of coating at least a portion of the tubular scaffold with a composition comprising a pharmaceutical agent. In a refinement, the composition further comprises a coating polymer. In further refinement, at least 90% of the surface area of the pharmaceutical agent is encapsulated in the coating polymer. In a further refinement, the coating polymer comprises a bioabsorbable polymer. In a further refinement, the bioabsorbable polymer is selected from the group consisting of polylactides (PLA); poly(lactide-co-glycolide) (PLGA); polyanhydrides; polyorthoesters; poly(N -(2- hydroxypropyl) methacrylamide ); poly( dl-lactide) (DLPLA); poly(l-lactide) (LPLA); polyglycolide (PGA); poly(dioxanone) (PDO); poly(glycolide-cotrimethylene carbonate) (PGA-TMC); poly(l-lactide-co-glycolide) (PGA-LPLA); poly( dl-lactide-coglycolide) (PGA-DLPLA); poly(l-lactide-co-dl-lactide) (LPLA-DLPLA); poly(glycolide-co-trimethylene carbonate-co-dioxanone) (PDO-PGA-TMC), polyarginine, and mixtures or co-polymers thereof. In a further refinement, the biodegradable polymer is selected from the group consisting of PLGA, polyarginine, and mixtures thereof.

In one embodiment, the one or more polymer fibers are gel-spun from a gel composition comprising the polymer and a pharmaceutical agent. In one embodiment, the one or more polymer fibers are extruded from a liquid crystalline composition comprising the polymer and a pharmaceutical agent.

In a refinement, the pharmaceutical agent is a macrolide immunosuppressant. In a further refinement, the macrolide immunosuppressant is rapamycin or a derivative, a prodrug, a hydrate, an ester, a salt, a polymorph, a derivative or an analog thereof. In another further refinement, the macrolide immunosuppressant is selected from the group consisting of rapamycin, 40-0-(2-Hydroxyethyl)rapamycin ( everolimus ), 40-0-Benzyl-rapamycin, 40-0-( 4'-Hydroxymethyl)benzylrapamycin, 40-0-[ 4 '-( 1 ,2-Dihydroxyethyl) ]benzyl-rapamycin, 40-0-Allyl-rapamycin, 40-0-[3 '-(2,2-Dimethyl-1 ,3-dioxolan-4(S)-yl)-prop-2' -en-1 '-yl] -rapamycin, (2':E,4'S)-40-0-( 4',5'-Dihydroxypent-2'-en-1 '-yl)-rapamycin, 40-0-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin, 40-0-(3-Hydroxy)propylrapamycin, 40-0-( 6-Hydroxy)hexyl-rapamycin, 40-0-[2-(2-Hydroxy)ethoxy] ethyl-rapamycin, 40-0-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-0-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-0-(2-Acetoxy)ethyl-rapamycin, 40-0-(2-Nicotinoyloxy)ethyl-rapamycin, 40-0-[2-(NMorpholino)acetoxy] ethyl-rapamycin, 40-0-(2-N-Imidazolylacetoxy )ethyl-rapamycin, 40-0-[2-(NMethyl-N' -piperazinyl)acetoxy] ethyl-rapamycin, 3 9-0-Desmethyl-3 9, 40-0, 0-ethylene-rapamycin, (26R )-26-Dihydro-40-0-(2-hydroxy)ethyl-rapamycin, 28-0-Methyl-rapamycin, 40-0-(2-Aminoethyl)rapamycin,40-0-(2-Acetaminoethyl)-rapamycin, 40-0-(2-Nicotinamidoethyl)-rapamycin, 40-0-(2-(NMethyl-imidazo-2'-ylcarbethoxamido)ethyl)-rapamycin, 40-0-(2-Ethoxycarbonylaminoethyl)-rapamycin,40-0-(2-Tolylsulfonamidoethyl)-rapamycin, 40-0-[2-( 4',5'-Dicarboethoxy-1 ',2',3'-triazol-1 '-yl)-ethyl]rapamycin,4 2-Epi-( tetrazolyl)rapamycin ( tacrolimus ), and 4 2-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin. In a further refinement, the pharmaceutical agent is rapamycin.

BRIEF DESCRIPTION OF DRAWINGS

The features of the present invention are set forth with particularity in the appended claims. A better understanding of the features of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments.

FIG. 1 graphically illustrates an exemplary stent formed from a PLLA tube;
FIG. 2 shows an exemplary stent as crimped on the balloon delivery system;
FIG. 3 shows recoil test results of exemplary stents in Group 1 and Group 5 according to Example 15;
FIG. 4 shows foreshortening test results of exemplary stents in Group 1 and Group 5 according to Example 15;
FIG. 5 shows stent retention test results of exemplary stents in Group 1 and Group 5 according to Example 15;
FIG. 6 shows radial strength test results of exemplary stents in Group A, Group 1 and Group 5 according to Example 15;
FIG. 7 shows deployment compliance test results of an exemplary stent according to Example 15;
FIG. 8 graphically illustrate structure of an exemplary stent in Group A according to Example 15 after deployment;
FIG. 9 graphically illustrate structure of an exemplary stent in Group 1 according to Example 15 after deployment; and
FIG. 10 graphically illustrates structure of an exemplary stent in Group 5 according to Example 15 after deployment.

DETAILED DESCRIPTION OF THE DISCLOSURE

The present disclosure is explained in greater detail below. This description is not intended to be a detailed catalog of all the different ways in which the present disclosure may be implemented, or all the features that may be added to the present disclosure. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the present disclosure. Hence, the following specification is intended to illustrate some particular embodiments of the present disclosure, and not to exhaustively specify all permutations, combinations and variations thereof.

Bioabsorbable Biomedical Implant

Fully bioabsorbable biomedical implants, such as stents made of polymers without metal structural reinforcements, provide several desirable features over metal-based biomedical implants. Yet, the development of fully bioabsorbable polymer stents remains challenging to this date. As bioabsorbable polymer materials used to make the polymer stents are generally weaker than metals (e.g. steel), polymer stents with structural strength and integrity similar to metal stents need to be made of polymer struts with average thickness much greater than that of the metal struts (e.g. greater or significantly greater than 120 µm).

It is contemplated in the present disclosure that the increased strut thickness, while improving the structural strength and integrity of the stents, may adversely affect one or more desirable characteristics of the polymer stent. For example, the thicker struts may result in a stent with larger overall stent profile and less flexibility, and hence more difficult to navigate within blood vessels before deployment. The thicker struts may also lead to lower deformability that limits range of deployment (e.g. less than 10% overexpansion above nominal diameter, or less than about 0.5 mm in a vascular stent). In addition, the thicker struts may take longer to be fully dissolved or degraded, such as between three to five years.

According to the claimed invention, a biomedical implant is disclosed as comprising:

a tubular scaffold comprising a plurality of interconnected bioabsorbable polymer struts, the interconnected polymer struts defining a plurality of deformable cells,
wherein the tubular scaffold includes polymer chains that are circumferential aligned along a center axis of the tubular scaffold, so that the tubular scaffold has an average axial elastic modulus along a center axis of the tubular scaffold and an average circumferential elastic modulus orthogonal to the center axis of the tubular scaffold, the average circumferential elastic modulus being greater than the average axial elastic modulus,
a pharmaceutical agent incorporated to the tubular scaffold,
wherein at least a portion of the tubular scaffold is covered with a coating comprising the pharmaceutical agent which is a macrolide immunosuppressant in crystalline form and a bioabsorbable coating polymer,
wherein the coating process involves the dry powder spraying of the pharmaceutical agent and of the polymer that is also dry powder sprayed, whereby the spraying of the agent and the polymer is sequential or simultaneous, and
wherein the polymer struts have an average thickness of no more than 120 µm.

In some examples, the features of the present disclosure, alone or in combination, allow the formation of a tubular scaffold of polymer struts that are not structurally reinforced with a metal material or non-metal reinforcement material that may negatively affect features such as bioabsorbability, strut thickness, wall thickness, radial strength, recoil, stent retention, foreshortening, burst pressure, and/or ease of manufacturing and application (deployment, etc).

Average Strut Thickness

In one embodiment, the polymer struts have an average strut thickness of no more than 100 µm. In another embodiment, the polymer struts have an average strut thickness of no more than 90 µm. In another embodiment, the polymer struts have an average strut thickness of no more than 80 µm. In another embodiment, the polymer struts have an average strut thickness of no more than 70 µm. In another embodiment, the polymer struts have an average strut thickness of no more than 60 µm. In another embodiment, the polymer struts have an average strut thickness of no more than 50 µm.

In one embodiment, the polymer struts have an average strut thickness of from 50 µm to 120 µm. In one embodiment, the polymer struts have an average strut thickness of from 60 µm to 120 µm. In one embodiment, the polymer struts have an average strut thickness of from 70 µm to 120 µm. In one embodiment, the polymer struts have an average strut thickness of from 80 µm to 120 µm. In one embodiment, the polymer struts have an average strut thickness of from 90 µm to 120 µm. In one embodiment, the polymer struts have an average strut thickness of from 100 µm to 120 µm.

In one embodiment, the polymer struts have an average strut thickness of from 50 µm to about 100 µm. In one embodiment, the polymer struts have an average strut thickness of from 60 µm to about 100 µm. In one embodiment, the polymer struts have an average strut thickness of from 70 µm to about 100 µm. In one embodiment, the polymer struts have an average strut thickness of from 80 µm to about 100 µm. In one embodiment, the polymer struts have an average strut thickness of from 90 µm to about 100 µm.

In one embodiment, the polymer struts have an average strut thickness of from 50 µm to about 90 µm. In one embodiment, the polymer struts have an average strut thickness of from 60 µm to about 90 µm. In one embodiment, the polymer struts have an average strut thickness of from 70 µm to about 90 µm . In one embodiment, the polymer struts have an average strut thickness of from 80 µm to about 90 µm.

In one embodiment, the polymer struts have an average strut thickness of from 50 µm to about 80µm. In one embodiment, the polymer struts have an average strut thickness of from 60 µm to about 80 µm. In one embodiment, the polymer struts have an average strut thickness of from 70 µm to about 80 µm.

Structural Strength and Integrity

The structural strength and integrity of the disclosed bioabsorbable biomedical implants can be characterized by one or combinations of the following methods.

Radial Strength Testing

This test is conducted to determine and graphically represent the change in stent internal diameter as a function of circumferential pressure and to determine the pressure at which deformation is no longer completely reversible for the disclosed stent. The stents are deployed to nominal pressure and removed from the delivery system. The stents are placed into a sleeve approximately 1 mm larger than the stent diameter. A vacuum is then applied and outer diameter measurements taken at various pressures. The bioabsorbable implants according to the present disclosure should maintain a minimum of at least 50 percent of the original stent diameter after a 50 mm Hg pressure is applied. Some bioabsorbable implants according to the present disclosure should maintain a minimum of at least 80 percent of the original stent diameter after a 50 mm Hg pressure is applied.

Stent Recoil Testing

This test was conducted to quantify the amount of elastic recoil. The stent delivery system is inflated to nominal pressure (9ATM) and the balloon is removed allowing for recoil to occur. The inner diameter at each end of the stent is recorded. Recoil is calculated subtracting the recoiled stent inner diameter from the pre-recoil inner diameter. In some embodiment, recoil is tested at a pressure of 16 ATM and expressed as"% recoil" (i.e. the ratio of radial recoil distance and the pre-recoil inner diameter.

Stent Expansion Testing

This test is conducted to determine if the plastic deformation experienced by the stent when expanded from the compressed profile to the final maximum deployed diameter (i.e. over-deployed diameter) can produce crack initiation for the disclosed stent. The sample stents are deployed up to their largest possible diameters by inflating each delivery system up to balloon failure. Each stent is examined at 45X magnification for potential cracks.

Maximum Pressure (burst test) Testing

This test is conducted to demonstrate that the delivery system (with mounted stent) will not experience balloon, shaft, proximal adaptation or proximal/distal seal loss of integrity at or below the pressure required to expand the stent to its labeled diameter. Stent delivery systems that had been subjected to all manufacturing and sterilization procedures were pressurized to 90psi with pressure held for 15 seconds and released for 3 seconds. The cycle was then repeated, increasing inflation pressure by 15psi each cycle until failure.

In one embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg. In another embodiment, the tubular scaffold maintains at least 60% of its nominal luminal cross sectional area under a pressure load of 50mmHg. In another embodiment, the tubular scaffold maintains at least 70% of its nominal luminal cross sectional area under a pressure load of 50mmHg. In another embodiment, the tubular scaffold maintains at least 80% of its nominal luminal cross sectional area under a pressure load of 50mmHg. In another embodiment, the tubular scaffold maintains at least 90% of its nominal luminal cross sectional area under a pressure load of 50mmHg. In another embodiment, the tubular scaffold maintains at least 95% of its nominal luminal cross sectional area under a pressure load of 50mmHg.

In one embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg upon 2 months of exposure to saline in vitro. In another embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg upon 2 month in vivo.

In one embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg upon 3 months of exposure to saline in vitro. In another embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg upon 3 month in vivo.

In one embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg upon 4 months of exposure to saline in vitro. In another embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg upon 4 month in vivo.

In one embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg upon 6 months of exposure to saline in vitro. In another embodiment, the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 50mmHg upon 6 month in vivo.

Polymer Chain Orientation Strut-Longitudinal Orientation

In one embodiment, which is not according to the claimed invention, each polymer strut includes polymer chains that are longitudinally aligned along a center axis of the polymer strut. In one example, the polymer struts include crystalline domains, in which the polymer chains are longitudinally aligned along the center axes of the polymer struts. In another example, more than 50% of polymer chains in the polymer struts or the crystalline domains are longitudinally aligned along the center axes of the polymer struts. In another example, more than 55% of the polymer chains or the crystalline domains in the polymer struts are longitudinally aligned along the center axes of the polymer struts. In another example, more than 60% of the polymer chains in the polymer struts or the crystalline domains are longitudinally aligned along the center axes of the polymer struts. In another example, more than 65% of the polymer chains in the polymer struts or the crystalline domains are longitudinally aligned along the center axes of the polymer struts. In another example, more than 70% of the polymer chains in the polymer struts or the crystalline domains are longitudinally aligned along the center axes of the polymer struts. In another example, more than 75% of the polymer chains in the polymer struts or the crystalline domains are longitudinally aligned along the center axes of the polymer struts. In another example, more than 80% of the polymer chains in the polymer struts or the crystalline domains are longitudinally aligned along the center axes of the polymer struts. In another example, more than 85% of the polymer chains in the polymer struts or the crystalline domains are longitudinally aligned along the center axes of the polymer struts. In another example, more than 90% of the polymer chains in the polymer struts or the crystalline domains are longitudinally aligned along the center axes of the polymer struts. In another example, more than 95% of the polymer chains in the polymer struts or the crystalline domains are longitudinally aligned along the center axes of the polymer struts.

As a result of the strut-longitudinal polymer chain orientation, the polymer struts have anisotropic elastic modulus. For example, the polymer struts have an average longitudinal elastic modulus along the center axes of the polymer struts and an average lateral elastic modulus orthogonal to the center axes of the polymer struts, the average longitudinal elastic modulus being greater than the average lateral elastic modulus.

In one example, the average longitudinal elastic modulus is at least 2 times the average lateral elastic modulus. In another example, the average longitudinal elastic modulus is at least 3 times the average lateral elastic modulus. In another example, the average longitudinal elastic modulus is at least 4 times the average lateral elastic modulus. In another example, the average longitudinal elastic modulus is at least 5 times the average lateral elastic modulus. In another example, the average longitudinal elastic modulus is at least 6 times the average lateral elastic modulus. In another example, the average longitudinal elastic modulus is at least 7 times the average lateral elastic modulus. In another example, the average longitudinal elastic modulus is at least 8 times the average lateral elastic modulus. In another example, the average longitudinal elastic modulus is at least 9 times the average lateral elastic modulus. In another example, the average longitudinal elastic modulus is at least 10 times the average lateral elastic modulus.

Scaffold-Axial Orientation

In one embodiment, which is not according to the claimed invention, the tubular scaffold includes polymer chains that are axially aligned along a center axis of the tubular scaffold. In one example, the polymer struts include crystalline domains, in which the polymer chains are axially aligned along a center axis of the tubular scaffold. In another example, more than 50% of polymer chains in the polymer struts or the crystalline domains are axially aligned along a center axis of the tubular scaffold. In another example, more than 55% of the polymer chains or the crystalline domains in the polymer struts are axially aligned along a center axis of the tubular scaffold. In another example, more than 60% of the polymer chains in the polymer struts or the crystalline domains are axially aligned along a center axis of the tubular scaffold. In another example, more than 65% of the polymer chains in the polymer struts or the crystalline domains are axially aligned along a center axis of the tubular scaffold. In another example, more than 70% of the polymer chains in the polymer struts or the crystalline domains are axially aligned along a center axis of the tubular scaffold. In another example, more than 75% of the polymer chains in the polymer struts or the crystalline domains are axially aligned along a center axis of the tubular scaffold. In another example, more than 80% of the polymer chains in the polymer struts or the crystalline domains are axially aligned along a center axis of the tubular scaffold. In another example, more than 85% of the polymer chains in the polymer struts or the crystalline domains are axially aligned along a center axis of the tubular scaffold. In another example, more than 90% of the polymer chains in the polymer struts or the crystalline domains are axially aligned along a center axis of the tubular scaffold. In another example, more than 95% of the polymer chains in the polymer struts or the crystalline domains are axially aligned along a center axis of the tubular scaffold.

As a result of the scaffold-axial polymer chain orientation, the tubular scaffold has anisotropic elastic modulus. For example, the tubular scaffold has an average axial elastic modulus along a center axis of the tubular scaffold and an average circumferential elastic modulus orthogonally surrounding a center axis of the tubular scaffold, the average axial elastic modulus being greater than the average circumferential elastic modulus.

In one example, the average axial elastic modulus is at least 2 times the average circumferential elastic modulus. In another example, the average axial elastic modulus is at least 3 times the average circumferential elastic modulus. In another example, the average axial elastic modulus is at least 4 times the average circumferential elastic modulus. In another example, the average axial elastic modulus is at least 5 times the average circumferential elastic modulus. In another example, the average axial elastic modulus is at least 6 times the average circumferential elastic modulus. In another example, the average axial elastic modulus is at least 7 times the average circumferential elastic modulus. In another example, the average axial elastic modulus is at least 8 times the average circumferential elastic modulus. In another example, the average axial elastic modulus is at least 9 times the average circumferential elastic modulus. In another example, the average axial elastic modulus is at least 10 times the average circumferential elastic modulus.

Scaffold- Circumferential Orientation

According to the claimed invention, the tubular scaffold includes polymer chains that are circumferential aligned, i.e. orthogonally surrounding a center axis of the tubular scaffold. In one embodiment, the polymer struts include crystalline domains, in which the polymer chains are circumferential aligned. In another embodiment, more than 50% of polymer chains in the polymer struts or the crystalline domains are circumferential aligned. In another embodiment, more than 55% of the polymer chains or the crystalline domains in the polymer struts are circumferential aligned. In another embodiment, more than 60% of the polymer chains in the polymer struts or the crystalline domains are circumferential aligned. In another embodiment, more than 65% of the polymer chains in the polymer struts or the crystalline domains are circumferential aligned. In another embodiment, more than 70% of the polymer chains in the polymer struts or the crystalline domains are circumferential aligned. In another embodiment, more than 75% of the polymer chains in the polymer struts or the crystalline domains are circumferential aligned. In another embodiment, more than 80% of the polymer chains in the polymer struts or the crystalline domains are circumferential aligned. In another embodiment, more than 85% of the polymer chains in the polymer struts or the crystalline domains are circumferential aligned. In another embodiment, more than 90% of the polymer chains in the polymer struts or the crystalline domains are circumferential aligned. In another embodiment, more than 95% of the polymer chains in the polymer struts or the crystalline domains are circumferential aligned.

As a result of the scaffold-circumferential polymer chain orientation, the tubular scaffold has anisotropic elastic modulus. For example, the tubular scaffold has an average axial elastic modulus along a center axis of the tubular scaffold and an average circumferential elastic modulus orthogonal to a center axis of the tubular scaffold, the average circumferential elastic modulus being greater than the average axial elastic modulus.

In one embodiment, the average circumferential elastic modulus is at least 2 times the average axial elastic modulus. In another embodiment, the average circumferential elastic modulus is at least 3 times the average axial elastic modulus. In another embodiment, the average circumferential elastic modulus is at least 4 times the average axial elastic modulus. In another embodiment, the average circumferential elastic modulus is at least 5 times the average axial elastic modulus. In another embodiment, the average circumferential elastic modulus is at least 6 times the average axial elastic modulus. In another embodiment, the average circumferential elastic modulus is at least 7 times the average axial elastic modulus. In another embodiment, the average circumferential elastic modulus is at least 8 times the average axial elastic modulus. In another embodiment, the average circumferential elastic modulus is at least 9 times the average axial elastic modulus. In another embodiment, the average circumferential elastic modulus is at least 10 times the average axial elastic modulus.

Polymer Tube

In some embodiments, the disclosed tubular scaffold is formed from a polymer tube, such as by laser cutting, water jet cutting or abrasive water jet cutting. Alternatively, the tubular scaffold can be formed from the polymer tube through photochemical etching or chemical etching. In some embodiment, the tubular scaffold formed from polymer tube also has the scaffold-circumferential, i.e. according to the claimed invention, or scaffold-axial (which is not according to the claimed invention) orientation disclosed herein. In some embodiment, which is also not according to the claimed invention, the tubular scaffold formed from polymer tube does not have the scaffold- circumferential or scaffold-axial orientation disclosed herein but has other characteristics that contribute to the mechanical and physical features of the disclosed tubular scaffold, including but not limited to, strut thickness, wall thickness, radial strength, recoil, stent retention, foreshortening, and burst pressure, as provided herein. In some embodiments, the features of the present disclosure, alone or in combination, allow the formation of a tubular scaffold of polymer struts that are not structurally reinforced with a metal material or non-metal reinforcement material that may negatively affect features such as bioabsorbability, strut thickness, wall thickness, radial strength, recoil, stent retention, foreshortening, burst pressure, and/ or ease of manufacturing and application (deployment, etc).

According to the claimed invention, the tubular scaffold has an average strut thickness of no more than 120 µm. In some embodiments, the polymer struts have an average strut thickness of 100 µm to 103 µm.

In some embodiments, the polymer struts have an average strut thickness of from 60 µm to about 120 µm.

In some embodiments, the polymer struts have an average strut thickness of from 60 µm to about 100 µm.

In some embodiments, the polymer struts have an average strut thickness of from 70 µm to 120 µm. In some embodiments, the polymer struts have an average strut thickness of from 70 µm to about 100 µm.

In some embodiments, the polymer struts have an average strut thickness of from 80 µm to 120 µm. In some embodiments, the polymer struts have an average strut thickness of from 80 µm to about 110 µm. In some embodiments, the polymer struts have an average strut thickness of from 80 µm to about 100 µm.

In some embodiments, the polymer struts have an average strut thickness of from 90 µm to 120 µm. In some embodiments, the polymer struts have an average strut thickness of from 90 µm to about 100 µm.

As used in the present disclosure, the term "strut thickness" refers to the thickness of the strut when the tubular scaffold is viewed from the side, and the term "wall thickness" refers to the wall thickness of the polymer tube, i.e. when the tubular scaffold is viewed in the axial direction. For example, in the non-limiting embodiment illustrated in FIG. 1, the strut thickness refers to the thickness of the strut as show on the left (indicated on the left side of FIG. 1) and the wall thickness refers to the wall thickness of the tubular scaffold or the wall thickness of the polymer tube ((indicated on the right side of FIG. 1). In addition, the term "about" refers to a variation of ±10%, as customarily understood in the technical field of the present disclosure.

In some embodiments, the tubular scaffold has an average wall thickness of from 80 µm to about 100 µm.

In some embodiments, the tubular scaffold has an average wall thickness of from 90 µm to about 100 µm.

Stress at Yield

In some embodiments, the polymer tube has higher radial stress at yield than axial stress at yield. In one embodiment, the polymer tube has a radial stress at yield that is 5% higher, 6% higher, 7% higher, 8% higher, 9% higher, 10% higher, 11% higher, 12% higher, 13% higher, 14% higher, 15% higher, 16% higher, 17% higher, 18% higher, 20% higher, 21% higher, 22% higher, 23% higher, 24% higher, 25% higher, 30% higher, 35% higher, 40% higher, 45% higher, or 50% higher than the axial stress at yield.

In some embodiments, the radial stress at yield of the polymer tube ranges from 50 MPa to 200 MPa, from 60 MPa to 180 MPa, from 70 MPa to 150 MPa, from 70 MPa to 140 MPa, from 70 MPa to 130 MPa, from 70 MPa to 120 MPa, from 70 MPa to µ0 MPa, from 70 MPa to 100 MPa, or from 75 MPa to 85 MPa. In some embodiments, the radial stress at yield of the polymer tube is 80 MPa. In some embodiment, the radial stress at yield is 50 MPa, 55 MPa, 60 MPa, 65 MPa, 70 MPa, 72 MPa, 74 MPa, 76 MPa, 78 MPa, 80 MPa, 82 MPa, 84 MPa, 86 MPa, 88 MPa, 90 MPa, 92 MPa, 94 MPa, 96 MPa, 98 MPa, 100 MPa, 105 MPa, 110 MPa, 115 MPa, 120 MPa, 125 MPa, 130 MPa, 135 MPa, 140 MPa, 145 MPa, 150 MPa, 155 MPa, 160 MPa, 165 MPa, 170 MPa, 1750 MPa, 180 MPa, 185 MPa, 190 MPa, 195 MPa, or 200 MPa.

In some embodiments, the axial stress at yield of the polymer tube ranges from 40 MPa to 160 MPa, from 50 MPa to 150 MPa, from 60 MPa to 150 MPa, from 60 MPa to 140 MPa, from 60 MPa to 130 MPa, from 60 MPa to 120 MPa, from 60 MPa to µ0 MPa, from 60 MPa to 100 MPa, from 60 MPa to 90 MPa, from 60 MPa to 80 MPa, or from 65 MPa to 75 MPa. In some embodiment, the axial stress at yield of the polymer tube ranges is 70 MPa. In some embodiment, the axial stress at yield is 40 MPa, 45 MPa, 50 MPa, 55 MPa, 60 MPa, 62 MPa, 64 MPa, 66 MPa, 68MPa, 70 MPa, 72 MPa, 74 MPa, 76 MPa, 78 MPa, 80 MPa, 82 MPa, 84 MPa, 86 MPa, 88 MPa, 90 MPa, 95 MPa, 100 MPa, 105 MPa, µ0 MPa, µ5 MPa, 120 MPa, 125 MPa, 130 MPa, 135 MPa, 140 MPa, 145 MPa, 150 MPa, 155 MPa, or 160 MPa.

Without wishing to be bound by any particular theory, it is contemplated in the present disclosure that the radial stress at yield, the axial stress at yield, and/ or their relatively ratio contribute to the mechanical and physical features of the disclosed tubular scaffold, including but not limited to, strut thickness, wall thickness, radial strength, recoil, stent retention, foreshortening, and burst pressure.

Stress at Break

In some embodiments, the polymer tube has higher radial stress at break than axial stress at break. In one embodiment, the polymer tube has a radial stress at break that is 20% higher, 25% higher, 30% higher, 35% higher, 40% higher, 45% higher, 50% higher, 55% higher, 60% higher, 65% higher, 70% higher, 75% higher, 80% higher, 85% higher, 90% higher, 95% higher, 100% higher, 110% higher, 120% higher, 130% higher, 140% higher, 150% higher, 160% higher, 170% higher, 180% higher, 190% higher, or 200% higher than the axial stress at break.

In some embodiments, the radial stress at break of the polymer tube ranges from 100 MPa to 300 MPa, from 100 MPa to 250 MPa, from 100 MPa to 230 MPa, from 100 MPa to 200 MPa, from 100 MPa to 190 MPa, from 100 MPa to 180 MPa, from 100 MPa to 170 MPa, from 100 MPa to 160 MPa, from 100 MPa to 150 MPa, from 100 MPa to 140 MPa, from 100 MPa to 130 MPa, from 100 MPa to 125 MPa, or from 100 MPa to 120 MPa. In some embodiment, the radial stress at break is µ0 MPa. In some embodiment, the radial stress at break is 100 MPa, 105 MPa, 110 MPa, 115 MPa, 120 MPa, 125 MPa, 130 MPa, 135 MPa, 140 MPa, 145 MPa, 150 MPa, 155 MPa, 160 MPa, 165 MPa, 170 MPa, 175 MPa, 180MPa, 190MPa, 200MPa, 210MPa, 220MPa, 230MPa,240MPa,250MPa,260MPa,270MPa, 280MPa, 290MPa, or 300 MPa.

In some embodiments, the axial stress at break of the polymer tube ranges from 40 MPa to 200 MPa, from 40 MPa to 190 MPa, from 45 MPa to 180 MPa, from 50 MPa to 170 MPa, from 60 MPa to 160 MPa, from 60 MPa to 150 MPa, from 60 MPa to 140 MPa, from 60 MPa to 130 MPa, from 60 MPa to 120 MPa, from 60 MPa to 110 MPa, from 60 MPa to 100 MPa, from 60 MPa to 90 MPa, from 60 MPa to 80 MPa, or from 65 MPa to 75 MPa. In some embodiment, the axial stress at break of the polymer tube ranges is 70 MPa. In some embodiment, the axial stress at break is 40 MPa, 45 MPa, 50 MPa, 55 MPa, 60 MPa, 62 MPa, 64 MPa, 66 MPa, 68MPa, 70 MPa, 72 MPa, 74 MPa, 76 MPa, 78 MPa, 80 MPa, 82 MPa, 84 MPa, 86 MPa, 88 MPa, 90 MPa, 100 MPa, µ0 MPa, 120 MPa, 130 MPa, 140 MPa, 150 MPa, 160 MPa, 170 MPa, 180 MPa, 190 MPa, or 200 MPa.

Without wishing to be bound by any particular theory, it is contemplated in the present disclosure that the radial stress at break, the axial stress at break, and/ or their relatively ratio contribute to the mechanical and physical features of the disclosed tubular scaffold, including but not limited to, strut thickness, wall thickness, radial strength, recoil, stent retention, foreshortening, and burst pressure.

Strain at Yield

In some embodiments, the polymer tube has lower radial strain at yield than axial strain at yield. In one embodiment, the ratio of axial strain at yield and radial strain at yield is 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0.

In some embodiments, the radial strain at yield (expressed as "%") of the polymer tube ranges from 1% to 40%, 5% to 40%, 10% to 40%, 12% to 40%, 14% to 40%, 16% to 40%, 18% to 40%,20% to 40%, 22% to 40%, 24% to 40%, 24% to 38%, 24% to 36%, 24% to 34%, 26% to 34%, 28% to 34%, or 28% to 32%. In some embodiments, the radial stress at yield is 30%. In some embodiment, the radial stress at yield is 1%, 5%, 10%, 12%, 14%, 16%, 18%,20%,22%,24%,26%,28%,30%,32%,34%, 36%, 38%, or 40%.

In some embodiments, the axial strain at yield (expressed as "%") of the polymer tube ranges from 1% to 60%, 5% to 60%, 10% to 60%, 15% to 60%, 20% to 60%, 25% to 60%, 30% to 60%, 32% to 60%, 34% to 60%, 36% to 60%, 38% to 60%,40% to 60%, 40% to 58%, 40% to 56%, 40% to 54%, 40% to 52%, 40% to 50%, 40% to 48%, 42% to 48%, 44% to 48%, or 44% to 46%. In some embodiments, the radial stress at yield is 45%. In some embodiment, the radial stress at yield is 1%, 5%, 10%, 15%, 20%, 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, 40%, 41%,42%,43%,44%,45%,46%,47%, 48%, 49%, 50%, 52%, 54%, 56%, 58%, or 60%.

Without wishing to be bound by any particular theory, it is contemplated in the present disclosure that the radial strain at yield, the axial strain at yield, and/ or their relatively ratio contribute to the mechanical and physical features of the disclosed tubular scaffold, including but not limited to, strut thickness, wall thickness, radial strength, recoil, stent retention, foreshortening, and burst pressure.

Strain at Break

In some embodiments, the polymer tube has lower radial strain at break than axial strain at break. In one embodiment, the ratio of axial strain at break and radial strain at break is 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.2, 4,.4, 4.6, 4.8 or 5.0.

In some embodiments, the radial strain at break (expressed as "%") of the polymer tube ranges from 50% to 200%, 50% to 195%, 55% to 195%, 55% to 190%, 60% to 190%, 60% to 185%, 65% to 185%, 65%to 180%, 70%to 180%, 70% to 175%, 75%to 175%, 75% to 170%, 80% to 170%, 80% to 165%, 85% to 165%, 85% to 160%, 90% to 160%, 90% to 155%, 95% to 155%, 95% to 150%, 100% to 150%, 105% to 150%, 105% to 145%, 110% to 145%, 110% to 140%, 115% to 140%, 115% to 135%, 120% to 135%, or 120% to 130%. In some embodiments, the radial stress at break is 125%. In some embodiment, the radial stress at break is 50%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 105%, 110%, 115%, 120%, 125%, 130%, 135%, 140%, 145%, 150%, 155%, 160%, 165%, 170%, 175%, 180%, 185%, 190%, 195%, or 200%.

In some embodiments, the axial strain at break (expressed as "%") of the polymer tube ranges from 100% to 1000%, 120% to 1000%, 140% to 1000%, 160% to 1000%, 180% to 1000%, 200% to 1000%, 200% to 900%, 200% to 850%, 200% to 800%, 200% to 750%, 200% to 700%, 200% to 650%, 200% to 600%, 200% to 550%, 200% to 500%, 200% to 400%, 220% to 400%, 240% to 400%, 260% to 400%, 280% to 400%, 280% to 380%, 300% to 380%, 300% to 360%, 320% to 360%, 320% to 350%, or 330% to 350%. In some embodiments, the radial stress at yield is 340%. In some embodiment, the radial stress at yield is 100%, 120%, 140%, 160%, 180%, 200%, 220%, 240%, 260%, 280%, 300%, 320%, 340%, 360%, 380%, 400%, 450%, 500%, 550%, 600%, 650%, 700%,750%, 800%, 850%, 900%, 950%, or 1000%.

Without wishing to be bound by any particular theory, it is contemplated in the present disclosure that the radial strain at break, the axial strain at break, and/ or their relatively ratio contribute to the mechanical and physical features of the disclosed tubular scaffold, including but not limited to, strut thickness, wall thickness, radial strength, recoil, stent retention, foreshortening, and burst pressure.

Deformation Angle

Further, as a result of the polymer chain orientation, the polymer struts have an average deformation angle, i.e. the average angle between the polymer struts when deployed minus the average angle between the polymer struts when undeployed. In one embodiment, the polymer struts have an average deformation angle of at least 90 degrees. In another embodiment, the polymer struts have an average deformation angle of at least 85 degrees. In another embodiment, the polymer struts have an average deformation angle of at least 80 degrees. In another embodiment, the polymer struts have an average deformation angle of at least 75 degrees. In another embodiment, the polymer struts have an average deformation angle of at least 70 degrees. In another embodiment, the polymer struts have an average deformation angle of at least 65 degrees. In another embodiment, the polymer struts have an average deformation angle of at least 60 degrees. In another embodiment, the polymer struts have an average deformation angle of at least 55 degrees. In another embodiment, the polymer struts have an average deformation angle of at least 50 degrees. In another embodiment, the polymer struts have an average deformation angle of at least 45 degrees. In another embodiment, the polymer struts have an average deformation angle of at least 40 degrees. In another example, the polymer struts have an average deformation angle of at least 30 degrees. Without wishing to be bound by any particular theory, it is contemplated that the configuration of the polymer struts according to the specified deformation angle improves the deformability of the polymer stent made of chain-oriented polymers.

Bioabsorbable Polymer Materials

In one embodiment, the polymer struts comprises a gel-spun polymer material. In a refinement, the polymer struts are not structurally reinforced with a metal material. In a further refinement, the gelspun polymer material is selected from the group consisting of polylactides (PLA); poly(lactide-coglycolide) (PLGA); polyanhydrides; polyorthoesters; poly(N -(2-hydroxypropyl) methacrylamide); poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); poly(d-lactide) (DPLA); polyglycolide (PGA); poly( dioxanone) (PDO); poly(glycolide-co-trimethylene carbonate) (PGA-TMC); poly(l-lactide-coglycolide) (PGA-LPLA); poly( dl-lactide-co-glycolide) (PGA-DLPLA); poly(l-lactide-co-dl-lactide) (LPLA-DLPLA); poly(glycolide-co-trimethylene carbonate-co-dioxanone) (PDO-PGA-TMC), poly(lactic acid-co-caprolactone) (PLACL), and mixtures or co-polymers thereof.

In one refinement, the gel-spun polymer material is PLGA. In a further refinement, the PLGA has a ratio of lactic acid monomer to glycolic acid monomer ranging from 82:18 to 88:12. In a further refinement, the PLGA has a ratio of lactic acid monomer to glycolic acid monomer ranging from 72:28 to 78:22. In another further refinement, the PLGA has a ratio of lactic acid monomer to glycolic acid monomer ranging from 62:38 to 68:32. In another further refinement, the PLGA has a ratio of lactic acid monomer to glycolic acid monomer ranging from 47:53 to 53:47. In another further refinement, the PLGA has a ratio of lactic acid monomer to glycolic acid monomer of 50:50.

In another further refinement, the PLGA has a weight average molecular weight of about 8,000 Dalton to about 12,000 Dalton. In another further refinement, the PLGA has a weight average molecular weight of about 12,000 Dalton to about 16,000 Dalton. In another further refinement, the PLGA has a weight average molecular weight of up to about 90,000 Dalton. In another refinement, the gel-spun polymer material is PLA or LPLA. In another refinement, the gel-spun polymer material is PGA. In some embodiment, the gel spun polymer material (e.g. PLGA, LPLA, PLA, PGA) has a weight average molecular weight of at least 90,000 Dalton, and optionally at least 100,000 Dalton

In another refinement, the liquid crystalline polymer material has a crystallinity of at least 30%. In another refinement, the liquid crystalline polymer material has a crystallinity of at least 35%. In another refinement, the liquid crystalline polymer material has a crystallinity of at least 40%. In another refinement, the liquid crystalline polymer material has a crystallinity of at least 45%. In another refinement, the liquid crystalline polymer material has a crystallinity of at least 50%. In another refinement, the liquid crystalline polymer material has a crystallinity of at least 55%. In another refinement, the liquid crystalline polymer material has a crystallinity of at least 60%. In another refinement, the liquid crystalline polymer material has a crystallinity of at least 65%. In another refinement, the liquid crystalline polymer material has a crystallinity of at least 70%.

In another refinement, the liquid crystalline polymer material is PLA or LPLA. In another refinement, the liquid crystalline polymer material is PGA. In some embodiment, the liquid crystalline polymer material (e.g. LPLA, PLA, PGA) has a weight average molecular weight of at least 90,000 Dalton, and optionally at least 100,000 Dalton

In one embodiment, the polymer struts include a polymer material selected from the group consisting of polycarboxylic acids, cellulosic polymers, proteins, polypeptides, polyvinylpyrrolidone, maleic anhydride polymers, polyamides, polyvinyl alcohols, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters, aliphatic polyesters, polyurethanes, polystyrenes, copolymers, silicones, silicone containing polymers, polyalkyl siloxanes, polyorthoesters, polyanhydrides, copolymers of vinyl monomers, polycarbonates, polyethylenes, polypropytenes, polylactic acids, polylactides, polyglycolic acids, polyglycolides, polylactide-co-glycolides, polycaprolactones, poly(e-caprolactone)s, polyhydroxybutyrate valerates, polyacrylamides, polyethers, polyurethane dispersions, polyacrylates, acrylic latex dispersions, polyacrylic acid, polyalkyl methacrylates, polyalkylene-co-vinyl acetates, polyalkylenes, aliphatic polycarbonates polyhydroxyalkanoates, polytetrahalooalkylenes, poly(phosphasones ), and mixtures, combinations, and copolymers thereof.

In some embodiment, such as those with tubular scaffold formed from a polymer tube, the polymer struts are made of a polymer material selected from poly lactic acids, polylactides, polyglycolic acids, polyglycolides, or polylactide-co-glycolides. In some embodiment, the polymer material is selected from PLLA, PLA, or PGA. In some embodiment, the polymer material is PLLA. In a refinement, the PLLA used to form the polymer tube has Mn of 120,000-130,000, and Mw of 170,000 to 190,000, with Mw/Mn of 1.3 to 1.6. In another refinement, the PLLA used to form the polymer tube has Mn of 124,000-125,000, and Mw of 180,000 to 185,000, with Mw/Mn of 1.46.

Stent Deployment

In one embodiment, the tubular scaffold is expandable from an undeployed diameter to a nominal diameter without affecting the structural integrity of the tubular scaffold. In a refinement, the tubular scaffold is further expandable from the nominal diameter to an over-deployed diameter without affecting the structural integrity of the tubular scaffold.

In a further refinement, the over-deployed diameter is about 1.0 mm greater than the nominal diameter. In another further refinement, the over-deployed diameter is about 0.9 mm greater than the nominal diameter. In another further refinement, the over-deployed diameter is about 0.8 mm greater than the nominal diameter. In another further refinement, the over-deployed diameter is about 0.7 mm greater than the nominal diameter. In another further refinement, the over-deployed diameter is about 0.6 mm greater than the nominal diameter. In another further refinement, the over-deployed diameter is about 0.5 mm greater than the nominal diameter. In another further refinement, the over-deployed diameter is about 0.4 mm greater than the nominal diameter. In another further refinement, the overdeployed diameter is about 0.3 mm greater than the nominal diameter. In another further refinement, the over-deployed diameter is about 0.2 mm greater than the nominal diameter.

In one refinement, the tubular scaffold is expandable by an inflatable balloon positioned within the tubular scaffold. In a further refinement, the tubular scaffold has a deployed diameter of 2.25 mm at nominal balloon pressure. In another further refinement, the tubular scaffold has a deployed diameter of 2.5 mm at nominal balloon pressure. In another further refinement, the tubular scaffold has a deployed diameter of 3. 0 mm at nominal balloon pressure. In another further refinement, the tubular scaffold has a deployed diameter of 3.5 mm at nominal balloon pressure. In another further refinement, the tubular scaffold has a deployed diameter of 4.0 mm at nominal balloon pressure. In another further refinement, the tubular scaffold has a deployed diameter of 4.5 mm at nominal balloon pressure. The nominal balloon pressure may be dependent on the material and design of the balloon. As a non-limiting example, the nominal balloon pressure is 6 atmospheres. As another example, the nominal balloon pressure is 9 ATM.

Many methods for forming wire- or filament-based stents can be used to make the bioabsorbable stents disclosed herein. For example, the methods for forming Wallstent (Boston Scientific), S7 (Medtronic), AngioStent (AngioDynamics), Strecker (Boston Scientific), Expander (Medicorp), Horizon Prostatic (Endocare), Endocoil (InStent), etc, can be used to in light of the present disclosure.

Drug Coating

According to the claimed invention, the biomedical implant further includes a pharmaceutical agent incorporated to the tubular scaffold. The pharmaceutical agent is a macrolide immunosuppressant. In a further refinement, the macrolide immunosuppressant is rapamycin or a derivative, a prodrug, a hydrate, an ester, a salt, a polymorph, a derivative or an analog thereof. In another further refinement, the macrolide immunosuppressant is selected from the group consisting of rapamycin, 40-0-(2- Hydroxyethyl)rapamycin ( everolimus ), 40-0-Benzyl-rapamycin, 40-0-( 4'-Hydroxymethyl)benzylrapamycin, 40-0-[ 4 '-( 1 ,2-Dihydroxyethyl) ]benzyl-rapamycin, 40-0-Allyl-rapamycin, 40-0-[3 '-(2,2- Dimethyl-1 ,3-dioxolan-4(S)-yl)-prop-2' -en-1 '-yl] -rapamycin, (2':E,4'S)-40-0-( 4',5'-Dihydroxypent-2'-en- 1 '-yl)-rapamycin, 40-0-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-0-(3-Hydroxy)propylrapamycin, 40-0-( 6-Hydroxy)hexyl-rapamycin, 40-0-[2-(2-Hydroxy)ethoxy] ethyl-rapamycin, 40-0- [(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-0-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-0-(2-Acetoxy)ethyl-rapamycin, 40-0-(2-Nicotinoyloxy)ethyl-rapamycin, 40-0-[2-(NMorpholino)acetoxy] ethyl-rapamycin, 40-0-(2-N-Imidazolylacetoxy )ethyl-rapamycin, 40-0-[2-(NMethyl-N' -piperazinyl)acetoxy] ethyl-rapamycin, 3 9-0-Desmethyl-3 9, 40-0, 0-ethylene-rapamycin, (26R )-26-Dihydro-40-0-(2-hydroxy)ethyl-rapamycin, 28-0-Methyl-rapamycin, 40-0-(2-Aminoethyl)rapamycin, 40-0-(2-Acetaminoethyl)-rapamycin, 40-0-(2-Nicotinamidoethyl)-rapamycin, 40-0-(2-(NMethyl-imidazo-2'-ylcarbethoxamido)ethyl)-rapamycin, 40-0-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-0-(2-Tolylsulfonamidoethyl)-rapamycin, 40-0-[2-( 4',5'-Dicarboethoxy-1 ',2',3'-triazol-1 '-yl)-ethyl]rapamycin, 4 2-Epi-( tetrazolyl)rapamycin ( tacrolimus ), and 4 2-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate ]rapamycin. In one refinement, the pharmaceutical agent is rapamycin.

In one refinement, the pharmaceutical agent is impregnated in at least a portion of the tubular scaffold. In a further refinement, the pharmaceutical agent is impregnated in the polymer struts. In a further refinement, the pharmaceutical agent is evenly distributed throughout the polymer struts.

According to the invention, at least a portion of the tubular scaffold is covered with a coating comprising the pharmaceutical agent. The coating further comprises a bioabsorbable coating polymer. In a further refinement, at least 90% of the surface area of the pharmaceutical agent is encapsulated in the coating polymer. In a further refinement, at least 85% of the surface area of the pharmaceutical agent is encapsulated in the coating polymer. In a further refinement, at least 80% of the surface area of the pharmaceutical agent is encapsulated in the coating polymer. In a further refinement, at least 75% of the surface area of the pharmaceutical agent is encapsulated in the coating polymer. In a further refinement, at least 70% of the surface area of the pharmaceutical agent is encapsulated in the coating polymer. In a further refinement, at least 65% of the surface area of the pharmaceutical agent is encapsulated in the coating polymer. In a further refinement, at least 60% of the surface area of the pharmaceutical agent is encapsulated in the coating polymer. In a further refinement, at least 55% of the surface area of the pharmaceutical agent is encapsulated in the coating polymer. In a further refinement, at least 50% of the surface area of the pharmaceutical agent is encapsulated in the coating polymer.

In a further embodiment, the pharmaceutical agent is impregnated in at least a portion of the tubular scaffold (e.g. evenly distributed throughout the tubular scaffold) and at least a portion of the tubular scaffold is covered with a coating comprising the pharmaceutical agent, such as in the manner discussed in the paragraph above.

In the invention, the coating polymer comprises a bioabsorbable polymer. In a further refinement, the bioabsorbable polymer is selected from the group consisting ofpolylactides (PLA); poly(lactide-co-glycolide) (PLGA); polyanhydrides; polyorthoesters; poly(N-(2-hydroxypropyl) methacrylamide); poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); polyglycolide (PGA); poly( dioxanone) (PDO); poly(glycolide-co-trimethylene carbonate) (PGA-TMC); poly(l-lactide-coglycolide) (PGA-LPLA); poly( dl-lactide-co-glycolide) (PGA-DLPLA); poly(l-lactide-co-dl-lactide) (LPLA-DLPLA); poly(glycolide-co-trimethylene carbonate-co-dioxanone) (PDO-PGA-TMC), polyarginine, and mixtures or co-polymers thereof. In a further refinement, the biodegradable polymer is selected from the group consisting of PLGA, polyarginine, and mixtures thereof.

Gel-Spun Polymer

According to another aspect of the present disclosure, which is not part of the claimed invention, a method of forming a gel-spun polyester fiber is described. The method includes the steps of forming a gel composition comprising the polyester and a solvent; extruding the gel composition through one or more orifices into a stream of drying air; and allowing the solvent to evaporate in the drying air to form the polyester fiber. In a refinement, the method further includes the step of drawing the extruded polymer.

In one example, the method further includes the step of cooling the polyester fiber in a liquid bath.

In one example, the gel composition are extruded through a spinneret.

In one example, the polyester is selected from the group consisting of polylactides (PLA); poly(lactide-co-glycolide) (PLGA); polyanhydrides; polyorthoesters; poly(N-(2-hydroxypropyl) methacrylamide); poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); poly(d-lactide) (DPLA); polyglycolide (PGA); poly( dioxanone) (PDO); poly(glycolide-co-trimethylene carbonate) (PGA-TMC); poly(l-lactide-co-glycolide) (PGA-LPLA); poly( dl-lactide-co-glycolide) (PGA-DLPLA); poly(l-lactideco-dl-lactide) (LPLA-DLPLA); poly(glycolide-co-trimethylene carbonate-co-dioxanone) (PDO-PGATMC), poly(lactic acid-co-caprolactone) (PLACL), and mixtures or co-polymers thereof. In a refinement, the polyester is PLGA. In another refinement, the polyester is PLA or LPLA.

Liquid Crystalline Polyester

According to another aspect of the present disclosure, which is not part of the claimed invention, a method of forming a liquid crystalline polyester fiber is described. The method includes the steps of forming a liquid crystalline composition comprising the polyester; and extruding the liquid crystalline composition to form the polyester fiber.

In one example, the polyester is in a melted state and wherein the method further comprises cooling the polyester fiber.

In one example, the liquid crystalline composition further comprises a solvent and wherein the method further comprises allowing the solvent to evaporate.

In one example, the polyester is selected from the group consisting of polylactides (PLA); poly(dl-lactide) (DLPLA); poly(l-lactide) (LPLA); poly(d-lactide) (DPLA); polyglycolide (PGA); poly( dioxanone) (PDO); poly(l-lactide-co-glycolide) (PGA-LPLA); poly(l-lactide-co-dl-lactide) (LPLADLPLA), poly(lactic acid-co-caprolactone) (PLACL), and mixtures or co-polymers thereof. In a refinement, the polyester is PLA. In another refinement, the polyester is LPLA. In another refinement, the polyester is PGA.

In some examplesof the disclosed method of forming a gel-spun polyester fiber and/ or forming a liquid crystalline polyester fiber, the polyester fiber has anisotropic elastic modulus. In a refinement, the polyester fiber comprises substantially aligned polymer chains.

Manufacturing of Bioabsorbable Stent

According to another aspect of the present disclosure, a method of forming a biomedical implant is disclosed. The method includes the steps of forming one or more polymer fibers comprising longitudinally aligned polymer chains; and interconnecting the polymer fibers to form a tubular scaffold, the tubular scaffold comprising a plurality of interconnected polymer struts to define a plurality of deformable cells.

Manufacturing of Tubular Scaffold Tubular Scaffold with Strut-Longitudinally Aligned Polvmer Orientation

In this non-limiting reference-example, which is not according to the claimed invention, the tubular scaffold of the present disclosure is made by forming a continuous wave form that includes a plurality of struts and a plurality of crowns. Each crown is a curved portion or turn within the wave form that connects adjacent struts to define the continuous wave form. In this example, the struts are substantially straight portions of the wave form. In other examples, the struts are slightly bent or have other shapes, such as a sinusoidal wave, for example. The wave form may be formed by a single polymer fiber or filament or a plurality of interconnected polymer fibers or filaments.

After the wave form is formed, the wave form is wrapped around a mandrel, a center axis of which defines the longitudinal axis of the tubular scaffold. The wave form may be wrapped at an angle that is not perpendicular to the longitudinal axis to form a plurality of helical turns that together generally form a helical coil in the shape of a helix.

The tubular scaffold also includes a plurality of connections that are configured to connect selected crowns of adjacent turns. In one embodiment, the tubular scaffold includes three connections per complete helix turn. In one embodiment, the tubular scaffold includes four connections per complete helix turn. In one embodiment, the tubular scaffold includes five connections per complete helix turn. Other connection numbers and configurations can also be used in light of the present disclosure. In a non-limiting example, the connections are created by fusing the selected crowns together. As used herein, "fusing" is defined as heating the target portions of materials to be fused together, with or without adding any additional material, to a level where the material in the target portions flow together, intermix with one another, and form a fusion when the materials cool down to, for example, room temperature.

Many methods for forming wire- or filament-based stents can be used to make the bioabsorbable stents disclosed herein. For example, the methods for forming Wallstent (Boston Scientific), S7 (Medtronic), AngioStent (AngioDynamics), Strecker (Boston Scientific), Expander (Medicorp), Horizon Prostatic (Endocare), Endocoil (InStent), etc, can be used to in light of the present disclosure

Tubular Scaffold with Scaffold-Axiallv Aligned Polymer Orientation

In this non-limiting reference-example, which is not according to the claimed invention, the tubular scaffold of the present disclosure is made by forming a polymer tube in which at least some polymer chains are aligned to a center axis of the polymer tube. In one example, the polymer tube is formed by (1) forming a gel composition comprising the polymer and a solvent; (2) extruding the gel composition to form a tubular structure; and (3) allowing the solvent to evaporate in drying air to form the polyester fiber. In a refinement, the extruded polymer tube undergoes another drawing process. In another embodiment, the polymer tube is formed by (1) forming a liquid crystalline composition (e.g. a melt) containing the polymer; and (2) extruding the liquid crystalline composition to form a tubular structure. In a refinement, the extruded polymer tube undergoes another longitudinal drawing process.

After the polymer tube is formed, the tubular scaffold can be made by laser-cutting a stent design from the polymer tube. In one example, the stent design is cut from the polymer tube using a polymer-compatible laser, such as carbon dioxide laser beam or other suitable laser cutting technologies in light of the present disclosure. In another example, the stent design is cut from the polymer tube by water jet cutting or abrasive water jet cutting. Alternatively, the tubular scaffold can be made through photochemical etching or chemical etching. Many slotted tube stent designs can be used to make the bioabsorbable stents disclosed herein. For example, suitable stent deigns may include, but are not limited to, bStent2 by Medtronic; BiodivYsio by Biocompatibles Ltd.; Velocity, Palmaz-Schatz 153/154, Palmaz-Schatz Crown by Cordis; Express by Boston Scientific; JOSTENT Flex by JOMED; Multi-Link PENTA, Multi-Link Rx, and Multi-Link Vision by Guidant; and NIR and NIR Flex by Medinol. Other stent designs may also be used in light of the present disclosure.

Tubular Scaffold with Scaffold-Circumferentially Aligned Polvmer Orientation

In this non-limiting example, the tubular scaffold of the present disclosure is made by first forming a polymer preform containing the bioabsorbable polymer material. In one embodiment, the polymer preform is molded or extruded from a gel composition containing the bioabsorbable polymer material. In another embodiment, the polymer preform is molded or extruded from a liquid crystalline composition containing the bioabsorbable polymer material. The polymer preform is then radially expanded and/ or stretched to desired inner diameter and wall thickness to form the polymer tube in which at least some polymer chains are circumferentially aligned (orthogonal to a center axis of the polymer tube). Without wishing to be bound by any particular theory, it is contemplated in the present disclosure that the radial expansion and stretching of the preform at least partially contribute to the circumferential alignment of the polymer chains in the polymer tube.

After the polymer tube is formed, the tubular scaffold can be made by laser-cutting a stent design from the polymer tube. In one embodiment, the stent design is cut from the polymer tube using a polymer-compatible laser, such as carbon dioxide laser beam or other suitable laser cutting technologies in light of the present disclosure. In another embodiment, the stent design is cut from the polymer tube by water jet cutting or abrasive water jet cutting. Alternatively, the tubular scaffold can be made through photochemical etching or chemical etching. Many slotted tube stent designs can be used to make the bioabsorbable stents disclosed herein. For example, suitable stent deigns may include, but are not limited to, bStent2 by Medtronic; BiodivYsio by Biocompatibles Ltd.; Velocity, Palmaz-Schatz 153/154, Palmaz-Schatz Crown by Cordis; Express by Boston Scientific; JOSTENT Flex by JOMED; Multi-Link PENTA, Multi-Link Rx, and Multi-Link Vision by Guidant; and NIR and NIR Flex by Medinol. Other stent designs may also be used in light of the present disclosure.

Coating of Tubular Scaffold

Provided herein are methods for coating the tubular scaffold (also referred to as substrate in this section) with a pharmaceutical or biological agent in powder form.

Provided herein are methods for depositing a coating polymer and a pharmaceutical or biological agent in powder form onto the substrate. The coating process provides a cost-effective, efficient method for depositing a combination of an inert polymer or polymers and a pharmaceutical or biological agent or agents, onto parts or all surfaces of a substrate, to form a coating that is of a pre-determined, desired thickness, conformal, substantially defect free, and uniform and the composition of the coating can be regulated. In particular, the coating process addresses the problem of existing coating processes, which do not allow for structural and morphological preservation of the agents deposited during the coating process.

One aspect of the invention entails the deposition of the pharmaceutical or biological agents as dry powder. Dry powder spraying is well known in the art, and dry powder spraying coupled with electrostatic capture has been described, for example in US Patents 5,470,603 ; 6,319,541 ; or 6,372,246 . The deposition of the polymer can be performed in any number of standard procedures, as the morphology of the polymer, so long as it provides coatings possessing the desired properties (e.g. thickness, conformity, defect-free, uniformity etc), is of less importance. The function of the polymer is primarily one of inert carrier matrix for the active components of the coating.

One aspect of the coating process is the combination of two or more of the dry powder, RESS and SEDS spraying techniques.

The coating process of the invention involves the dry powder spraying of a pharmaceutical agent, in a preferred particle size and morphology, into the same capture vessel as a polymer that is also dry powder sprayed, whereby the spraying of the agent and the polymer is sequential or simultaneous.

Another exampleof the coating process involves the dry powder spraying of an active biological agent, in a preferred particle size and possessing a particular activity, into the same capture vessel as a polymer that is also dry powder sprayed, whereby the spraying of the agent and the polymer is sequential or simultaneous.

Yet another exampleof the coating process involves the dry powder spraying of a pharmaceutical agent, in a preferred particle size and morphology, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the RESS spray process.

Yet another exampleof the coating process involves the dry powder spraying of an active biological agent, in a preferred particle size and possessing a particular activity, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the RESS spray process.

Yet another exampleof the coating process involves the dry powder spraying of a pharmaceutical agent, in a preferred particle size and morphology, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the SEDS spray process.

Yet another exampleof the coating process involves the dry powder spraying of an active biological agent, in a preferred particle size and possessing a particular activity, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the SEDS spray process.

In some examples, the RESS or the SEDS process used in forming the coating is performed with electrically charging the substrate. In some embodiments, the e-RESS or the e-SEDS process used in forming the coating is performed by creating an electrical potential between the substrate and the coating apparatus used in process. In some embodiment, the RESS or the SEDS process used in forming the coating is performed without electrically charging the substrate.

In further examplesof the coating process the substrates that have been coated with pharmaceutical or biological agents and polymers, as described in the above embodiments are then subjected to a sintering process. The sintering process takes place under benign conditions, which do not affect the structural and morphological integrity of the pharmaceutical and biological agents, and refers to a process by which the co-deposited pharmaceutical agent or biological agent-polymer matrix, becomes continuous and adherent to the substrate. This is achieved by treating the coated substrate with a compressed gas, compressed liquid or supercritical fluid at conditions such that it is a poor solvent of the polymers, a weak solvent of the polymers or a non-solvent for the polymers, the pharmaceutical agents and the biological agents, but an agent suitable for the treatment of polymer particles to form continuous polymer coatings. The sintering process takes place under conditions (e.g. mild temperatures), and using benign fluids (e.g. supercritical carbon dioxide) which will not affect the structural and morphological integrity of the pharmaceutical and biological agents. Other sintering processes, which do not affect the structural and morphological integrity of the pharmaceutical and biological agents may also be contemplated by the present invention.

In further examplesof the coating process, it is desirable to create coatings such that release of an active substance occurs with a predetermined elution profile when placed in the desired elution media. Coating properties can be modified in a variety of different ways in order to provide desirable elution profiles.

The chemical composition of the coating polymers can be varied, to provide greater or lesser amounts of coating polymers that will allow or restrict the elution of active substance. For example, if the intended elution media contain water, a higher content of coating polymers that swell in water, will allow for a faster elution of active substance. Conversely, a higher content of coating polymers that do not swell in aqueous media will result in a slower elution rate.

The coating properties can also be controlled by alternating coating polymer layers. Layers of coating polymers of different properties are deposited on the substrate in a sequential manner. By modifying the nature of the polymer deposited in each layer (e.g., depositing layers of different polymers) the elution profile of the coating is altered. The number of layers and the sequence in their deposition provide additional avenues for the design of coatings having controlled elution profiles.

The coating properties can also be modified by control of the macro and/ or microstructure of the polymer coating (diffusion pathways). This may be achieved by varying the coating process( es) or by using different sintering conditions.

The coating process provides several approaches for controlling the elution of a drug or several drugs. For example, in one embodiment, controlled elution is achieved by the segregation of different coating polymers (e.g. PEVA / PBMA). In another embodiment, control of elution is achieved by controlling the conditions during the sintering process such that controlled incomplete sintering of the polymer matrix is obtained, whereby the coating would retain some of the particle-like structure of the polymer particles as deposited. Incomplete sintering would provide pores/voids in the coating and allow additional pathways for elution of the drug, including drug elution around the polymer(s) instead of, or in addition to, elution through the polymer(s). The size of the pores or voids obtained through incomplete sintering of the polymer matrix may be obtained through several methods. For example, the rate of depressurization of a vessel in which the sintering process is carried out provides one avenue for controlling pore size. The size of the cavities or pores in the coating can be controlled by employing a porogen as an excipient and subsequent removal of at least a portion of the porogen, for example by treatment with a solvent of the porogen. Preferably, the porogen solvent comprises a densified gas (e.g.; carbon). In some embodiments the porogen is an SOA or other such hydrophobically derivatized carbohydrate. Removal of at least a portion of the porogen is preferably carried out during the sintering process.

In some aspects of the invention, the active substance elution profile is controllable by altering the coating polymer particle size. The method by which the polymer particles are deposited onto the substrate is thus varied to provide the desired elution rate. For example, for polymers released simultaneously through the same nozzle, RESS release from a supercritical solution would typically result in small polymer particles; RESS-like release from a mixture in a compressed gas usually generates larger polymer particles. Using the SEDS process can result in variable polymer particle size, depending on the particular SEDS conditions employed.

In further aspects of the coating process, the active substance elution profile is controllable by altering the coating polymer particle shape. One way to achieve variation in polymer particle shape is to alter the initial concentration of the polymers. At lower initial concentrations, polymers are deposited as small particles. At increased concentrations, larger particles are formed. At higher concentrations, the formed particles become elongated, until at high concentrations the elongated features become fiber-like and eventually become continuous fibers.

In yet other aspects of the coating process, the active substance elution profile is controllable by creating discrete domains of chemically different polymers. As described above, chemically different polymers will allow or restrict the elution of active substance in different elution media. By changing the position of such polymers in discrete macroscopic domains within the coating, the elution profiles will be adjustable. For example during a process whereby two different polymers are released sequentially through the same nozzle, particles of either polymer could be deposited to position them, for example, closer to the outside, the inside or the middle of the coating on the substrate. In another embodiment, the two polymers may be released simultaneously through two different nozzles at differing and/or alternating deposition rates, resulting in a similar effect. In a further embodiment, the deposition of eluting and non-eluting polymers is alternated to result in a fluctuating type of release. In yet other embodiments, the polymers are deposited to provide for a pulsatile release of active substance. Separation of the polymer(s) providing different domains for drug diffusion is achieved, for example, by subsequent spray of the polymers through same nozzle or by using multiple nozzles. Also, as described above, controlling the elution of the active substance may be achieved by layering of different polymers across the depth of the coating. A combination of domain separation and cross-depth layering is also contemplated for the design of coatings having controlled elution properties.

The deposition of active substance during any of these processes may be constant to provide even distribution throughout the coating, or the spraying of the active substance may be varied to result in differing amounts of active substance in the differing polymeric domains within the coating.

In further aspects of the coating process, the active substance elution profile is controllable by varying the coating sintering conditions. For example, incomplete sintering will create open spaces, or pores in the interstitial spaces between the polymer particles, which will enable faster eluting of active substance from the coating. Another way to utilize the sintering conditions for elution control would be to deliberately create irregular coatings by foaming during the sintering process. Rapid pressure release of a C0₂- or isobutylene-impregnated polymer film induces formation of foamed polymers which would create a coating with increased porosity and be very 'open' to diffusion/elution. Thus the elution profile would be controllable by manipulating the foaming conditions, which in turn controls the pore density and size.

Another advantage of the coating process is the ability to create a stent with a controlled (dialed in) drug-elution profile. Via the ability to have different materials in each layer of the laminate structure and the ability to control the location of drug(s) independently in these layers, the method enables a stent that could release drugs at very specific elution profiles, programmed sequential and/or parallel elution profiles. Also, the present invention allows controlled elution of one drug without affecting the elution of a second drug (or different doses of the same drug).

The embodiments incorporating a stent form or framework provide the ability to radiographically monitor the stent in deployment. In an alternative embodiment, the innerdiameter of the stent can be masked (e.g. by a non-conductive mandrel). Such masking would prevent additional layers from being on the interior diameter ( abluminal) surface of the stent. The resulting configuration may be desirable to provide preferential elution of the drug toward the vessel wall (luminal surface of the stent) where the therapeutic effect of anti-restenosis is desired, without providing the same antiproliferative drug(s) on the abluminal surface, where they may retard healing, which in turn is suspected to be a cause of late-stage safety problems with current DESs.

The coating process allows for employing a platform combining layer formation methods based on compressed fluid technologies; electrostatic capture and sintering methods. The platform results in drug eluting stents having enhanced therapeutic and mechanical properties. The coating process is particularly advantageous in that it employs optimized laminate polymer technology. In particular, the coating process allows the formation of discrete layers of specific drug platforms.

With the coating process provided herein the drugs and polymers are coated on the stent framework in discrete steps, which can be carried out simultaneously or alternately. This allows discrete deposition of the active agent (e.g.; a drug) within a polymer matrix thereby allowing the placement of more than one drug on a single medical device with or without an intervening polymer layer. For example, the present platform provides a dual drug eluting stent.

Some of the advantages provided by the coating process include employing compressed fluids (e.g., supercritical fluids, for example RESS based methods); solvent free deposition methodology; a platform that allows processing at lower temperatures thereby preserving the qualities of the active agent and the polymer matrix; the ability to incorporate two, three or more drugs while minimizing deleterious effects from direct interactions between the various drugs and/ or their excipients during the fabrication and/or storage of the drug eluting stents; a dry deposition; enhanced adhesion and mechanical properties of the layers on the stent framework; precision deposition and rapid batch processing; and ability to form intricate structures.

The coating process may provide a multi-drug delivery platform which produces strong, resilient and flexible drug eluting stents including an anti-restenosis drug (e.g.; a limus or taxol) and antithrombosis drug (e.g.; heparin or an analog thereof) and well characterized bioabsorbable polymers. The drug eluting stents provided herein minimize potential for thrombosis, in part, by reducing or totally eliminating thrombogenic polymers and reducing or totally eliminating residual drugs that could inhibit healing.

Definitions

As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.

The terms "bioabsorbable," "biodegradable," "bioerodible," "bioresorbable," and "resorbable" are art-recognized synonyms. These terms are used herein interchangeably. Bioabsorbable polymers typically differ from non-bioabsorbable polymers in that the former may be absorbed (e.g.; degraded) during use. In certain embodiments, such use involves in vivo use, such as in vivo therapy, and in other certain embodiments, such use involves in vitro use. In general, degradation attributable to biodegradability involves the degradation of a bioabsorbable polymer into its component subunits, or digestion, e.g., by a biochemical process, of the polymer into smaller, non-polymeric subunits. In certain embodiments, biodegradation may occur by enzymatic mediation, degradation in the presence of water (hydrolysis) and/ or other chemical species in the body, or both. The bioabsorbability of a polymer may be indicated in-vitro as described herein or by methods known to one of skill in the art. An in-vitro test for bioabsorbability of a polymer does not require living cells or other biologic materials to indicate bioabsorption properties (e.g. degradation, digestion). Thus, resorbtion, resorption, absorption, absorbtion, erosion may also be used synonymously with the terms "bioabsorbable," "biodegradable," "bioerodible," and "bioresorbable." Mechanisms of degradation of a bioabsorbable polymer may include, but are not limited to, bulk degradation, surface erosion, and combinations thereof.

As used herein, the term "biodegradation" encompasses both general types of biodegradation. The degradation rate of a biodegradable polymer often depends in part on a variety of factors, including the chemical identity of the linkage responsible for any degradation, the molecular weight, crystallinity, biostability, and degree of cross-linking of such polymer, the physical characteristics (e.g., shape and size) of the implant, and the mode and location of administration. For example, the greater the molecular weight, the higher the degree of crystallinity, and/or the greater the biostability, the biodegradation of any bioabsorbable polymer is usually slower.

"Degradation" as used herein refers to the conversion or reduction of a chemical compound to one less complex, e.g., by splitting off one or more groups of atoms. Degradation of the coating may reduce the coating's cohesive and adhesive binding to the device, thereby facilitating transfer of the coating to the intervention site

"Pharmaceutical agent" as used herein refers to any of a variety of drugs or pharmaceutical compounds that can be used as active agents to prevent or treat a disease (meaning any treatment of a disease in a mammal, including preventing the disease, i.e. causing the clinical symptoms of the disease not to develop; inhibiting the disease, i.e. arresting the development of clinical symptoms; and/or relieving the disease, i.e. causing the regression of clinical symptoms). It is possible that the pharmaceutical agents of the invention may also comprise two or more drugs or pharmaceutical compounds. Pharmaceutical agents, include but are not limited to antirestenotic agents, antidiabetics, analgesics, antiinflammatory agents, antirheumatics, antihypotensive agents, antihypertensive agents, psychoactive drugs, tranquillizers, antiemetics, muscle relaxants, glucocorticoids, agents for treating ulcerative colitis or Crohn's disease, antiallergics, antibiotics, antiepileptics, anticoagulants, antimycotics, antitussives, arteriosclerosis remedies, diuretics, proteins, peptides, enzymes, enzyme inhibitors, gout remedies, hormones and inhibitors thereof, cardiac glycosides, immunotherapeutic agents and cytokines, laxatives, lipid-lowering agents, migraine remedies, mineral products, otologicals, anti parkinson agents, thyroid therapeutic agents, spasmolytics, platelet aggregation inhibitors, vitamins, cytostatics and metastasis inhibitors, phytopharmaceuticals, chemotherapeutic agents and amino acids. Examples of suitable active ingredients are acarbose, antigens, beta-receptor blockers, non-steroidal antiinflammatory drugs {NSAIDs], cardiac glycosides, acetylsalicylic acid, virustatics, aclarubicin, acyclovir, cisplatin, actinomycin, alpha- and beta-sympatomimetics, ( dmeprazole, allopurinol, alprostadil, prostaglandins, amantadine, ambroxol, amlodipine, methotrexate, S-aminosalicylic acid, amitriptyline, amoxicillin, anastrozole, atenolol, azathioprine, balsalazide, beclomethasone, betahistine, bezafibrate, bicalutamide, diazepam and diazepam derivatives, budesonide, bufexamac, buprenorphine, methadone, calcium salts, potassium salts, magnesium salts, candesartan, carbamazepine, captopril, cefalosporins, cetirizine, chenodeoxycholic acid, ursodeoxycholic acid, theophylline and theophylline derivatives, trypsins, cimetidine, clarithromycin, clavulanic acid, clindamycin, clobutinol, clonidine, cotrimoxazole, codeine, caffeine, vitamin D and derivatives of vitamin D, colestyramine, cromoglicic acid, coumarin and coumarin derivatives, cysteine, cytarabine, cyclophosphamide, ciclosporin, cyproterone, cytabarine, dapiprazole, desogestrel, desonide, dihydralazine, diltiazem, ergot alkaloids, dimenhydrinate, dimethyl sulphoxide, dimeticone, domperidone and domperidan derivatives, dopamine, doxazosin, doxorubizin, doxylamine, dapiprazole, benzodiazepines, diclofenac, glycoside antibiotics, desipramine, econazole, ACE inhibitors, enalapril, ephedrine, epinephrine, epoetin and epoetin derivatives, morphinans, calcium antagonists, irinotecan, modafinil, orlistat, peptide antibiotics, phenytoin, riluzoles, risedronate, sildenafil, topiramate, macrolide antibiotics, oestrogen and oestrogen derivatives, progestogen and progestogen derivatives, testosterone and testosterone derivatives, androgen and androgen derivatives, ethenzamide, etofenamate, etofibrate, fenofibrate, etofylline, etoposide, famciclovir, famotidine, felodipine, fenofibrate, fentanyl, fenticonazole, gyrase inhibitors, fluconazole, fludarabine, fluarizine, fluorouracil, fluoxetine, flurbiprofen, ibuprofen, flutamide, fluvastatin, follitropin, formoterol, fosfomicin, furosemide, fusidic acid, gallopamil, ganciclovir, gemfibrozil, gentamicin, ginkgo, Saint John's wort, glibenclamide, urea derivatives as oral antidiabetics, glucagon, glucosamine and glucosamine derivatives, glutathione, glycerol and glycerol derivatives, hypothalamus hormones, goserelin, gyrase inhibitors, guanethidine, halofantrine, haloperidol, heparin and heparin derivatives, hyaluronic acid, hydralazine, hydrochlorothiazide and hydrochlorothiazide derivatives, salicylates, hydroxyzine, idarubicin, ifosfamide, imipramine, indometacin, indoramine, insulin, interferons, iodine and iodine derivatives, isoconazole, isoprenaline, glucitol and glucitol derivatives, itraconazole, ketoconazole, ketoprofen, ketotifen, lacidipine, lansoprazole, levodopa, levomethadone, thyroid hormones, lipoic acid and lipoic acid derivatives, lisinopril, lisuride, lofepramine, lomustine, loperamide, loratadine, maprotiline, mebendazole, mebeverine, meclozine, mefenamic acid, mefloquine, meloxicam, mepindolol, meprobamate, meropenem, mesalazine, mesuximide, metamizole, metformin, methotrexate, methylphenidate, methylprednisolone, metixene, metoclopramide, metoprolol, metronidazole, mianserin, miconazole, minocycline, minoxidil, misoprostol, mitomycin, mizolastine, moexipril, morphine and morphine derivatives, evening primrose, nalbuphine, naloxone, tilidine, naproxen, narcotine, natamycin, neostigmine, nicergoline, nicethamide, nifedipine, niflumic acid, nimodipine, nimorazole, nimustine, nisoldipine, adrenaline and adrenaline derivatives, norfloxacin, novamine sulfone, noscapine, nystatin, ofloxacin, olanzapine, olsalazine, omeprazole, omoconazole, ondansetron, oxaceprol, oxacillin, oxiconazole, oxymetazoline, pantoprazole, paracetamol, paroxetine, penciclovir, oral penicillins, pentazocine, pentifylline, pentoxifylline, perphenazine, pethidine, plant extracts, phenazone, pheniramine, barbituric acid derivatives, phenylbutazone, phenytoin, pimozide, pindolol, piperazine, piracetam, pirenzepine, piribedil, piroxicam, pramipexole, pravastatin, prazosin, procaine, promazine, propiverine, propranolol, propyphenazone, prostaglandins, protionamide, proxyphylline, quetiapine, quinapril, quinaprilat, ramipril, ranitidine, reproterol, reserpine, ribavirin, rifampicin, risperidone, ritonavir, ropinirole, roxatidine, roxithromycin, ruscogenin, rutoside and rutoside derivatives, sabadilla, salbutamol, salmeterol, scopolamine, selegiline, sertaconazole, sertindole, sertralion, silicates, sildenafil, simvastatin, sitosterol, sotalol, spaglumic acid, sparfloxacin, spectinomycin, spiramycin, spirapril, spironolactone, stavudine, streptomycin, sucralfate, sufentanil, sulbactam, sulphonamides, sulfasalazine, sulpiride, sultamicillin, sultiam, sumatriptan, suxamethonium chloride, tacrine, tacrolimus, taliolol, tamoxifen, taurolidine, tazarotene, temazepam, teniposide, tenoxicam, terazosin, terbinafine, terbutaline, terfenadine, terlipressin, tertatolol, tetracyclins, teryzoline, theobromine, theophylline, butizine, thiamazole, phenothiazines, thiotepa, tiagabine, tiapride, propionic acid derivatives, ticlopidine, timolol, tinidazole, tioconazole, tioguanine, tioxolone, tiropramide, tizanidine, tolazoline, tolbutamide, tolcapone, tolnaftate, tolperisone, topotecan, torasemide, antioestrogens, tramadol, tramazoline, trandolapril, tranylcypromine, trapidil, trazodone, triamcinolone and triamcinolone derivatives, triamterene, trifluperidol, trifluridine, trimethoprim, trimipramine, tripelennamine, triprolidine, trifosfamide, tromantadine, trometamol, tropalpin, troxerutine, tulobuterol, tyramine, tyrothricin, urapidil, ursodeoxycholic acid, chenodeoxycholic acid, valaciclovir, valproic acid, vancomycin, vecuronium chloride, Viagra, venlafaxine, verapamil, vidarabine, vigabatrin, viloazine, vinblastine, vincamine, vincristine, vindesine, vinorelbine, vinpocetine, viquidil, warfarin, xantinol nicotinate, xipamide, zafirlukast, zalcitabine, zidovudine, zolmitriptan, zolpidem, zoplicone, zotipine and the like. See, e.g., US Patent No. 6,897,205 ; see also US Patent No. 6,838,528 ; US Patent No. 6,497,729 .

Examples of therapeutic agents employed in conjunction with the invention include, rapamycin, 40-0-(2-Hydroxyethyl)rapamycin ( everolimus ), 40-0-Benzyl-rapamycin, 40-0-( 4'Hydroxymethyl) benzyl-rapamycin, 40-0-[ 4'-(1 ,2-Dihydroxyethyl) ]benzyl-rapamycin, 40-0-Allylrapamycin, 40-0-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1 '-yl]-rapamycin, (2':E,4'S)-40-0-( 4',5'-Dihydroxypent-2'-en-1 '-yl)-rapamycin, 40-0-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin, 40-0-(3-Hydroxy)propyl-rapamycin, 40-0-(6-Hydroxy)hexylrapamycin, 40-0-[2-(2-Hydroxy)ethoxy] ethyl-rapamycin, 40-0-[ (3 S )-2,2-Dimethyldioxolan-3-yl] methyl-rapamycin, 40-0-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-0-(2-Acetoxy)ethyl-rapamycin, 40-0-(2-34 Nicotinoyloxy)ethyl-rapamycin, 40-0-[2-(N-Morpholino )acetoxy] ethyl-rapamycin, 40-0-(2-N-Imidazolylacetoxy) ethyl-rapamycin, 40-0-[2-(N-Methyl-N' - piperazinyl)acetoxy] ethyl-rapamycin, 3 9-0-Desmethyl-3 9, 40-0, 0-ethylene-rapamycin, (26R )-26-Dihydro-40-0-(2-hydroxy)ethyl-rapamycin, 28-0-Methyl-rapamycin, 40-0-(2-Aminoethyl)-rapamycin, 40-0-(2-Acetaminoethyl)-rapamycin, 40-0-(2-Nicotinamidoethyl)-rapamycin, 40-0-(2-(N-Methyl-imidazo-2 '-ylcarbethoxamido )ethyl)-rapamycin, 40-0-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-0-(2-T olylsulfonamidoethyl)-rapamycin, 40-0-[2-(4',5'-Dicarboethoxy-1 ',2',3'-triazol-1 '-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus ), and 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate ]rapamycin (temsirolimus ).

The active ingredients may, if desired, also be used in the form of their pharmaceutically acceptable salts or derivatives (meaning salts which retain the biological effectiveness and properties of the compounds of this invention and which are not biologically or otherwise undesirable), and in the case of chiral active ingredients it is possible to employ both optically active isomers and racemates or mixtures of diastereoisomers.

"Stability" as used herein in refers to the stability of the drug in a polymer coating deposited on a substrate in its final product form (e.g., stability of the drug in a coated stent). The term stability will define 5% or less degradation of the drug in the final product form.

"Active biological agent" as used herein refers to a substance, originally produced by living organisms, that can be used to prevent or treat a disease (meaning any treatment of a disease in a mammal, including preventing the disease, i.e. causing the clinical symptoms of the disease not to develop; inhibiting the disease, i.e. arresting the development of clinical symptoms; and/or relieving the disease, i.e. causing the regression of clinical symptoms). It is possible that the active biological agents of the invention may also comprise two or more active biological agents or an active biological agent combined with a pharmaceutical agent, a stabilizing agent or chemical or biological entity. Although the active biological agent may have been originally produced by living organisms, those of the present invention may also have been synthetically prepared, or by methods combining biological isolation and synthetic modification. By way of a non-limiting example, a nucleic acid could be isolated form from a biological source, or prepared by traditional techniques, known to those skilled in the art of nucleic acid synthesis. Furthermore, the nucleic acid may be further modified to contain non-naturally occurring moieties. Non-limiting examples of active biological agents include peptides, proteins, enzymes, glycoproteins, nucleic acids (including deoxyribonucleotide or ribonucleotide polymers in either single or double stranded form, and unless otherwise limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides ), antisense nucleic acids, fatty acids, antimicrobials, vitamins, hormones, steroids, lipids, polysaccharides, carbohydrates and the like. They further include, but are not limited to, antirestenotic agents, antidiabetics, analgesics, antiinflammatory agents, antirheumatics, antihypotensive agents, antihypertensive agents, psychoactive drugs, tranquillizers, antiemetics, muscle relaxants, glucocorticoids, agents for treating ulcerative colitis or Crohn's disease, antiallergics, antibiotics, antiepileptics, anticoagulants, antimycotics, antitussives, arteriosclerosis remedies, diuretics, proteins, peptides, enzymes, enzyme inhibitors, gout remedies, hormones and inhibitors thereof, cardiac glycosides, immunotherapeutic agents and cytokines, laxatives, lipid-lowering agents, migraine remedies, mineral products, otologicals, anti parkinson agents, thyroid therapeutic agents, spasmolytics, platelet aggregation inhibitors, vitamins, cytostatics and metastasis inhibitors, phytopharmaceuticals and chemotherapeutic agents. Preferably, the active biological agent is a peptide, protein or enzyme, including derivatives and analogs of natural peptides, proteins and enzymes.

"Activity" as used herein refers to the ability of a pharmaceutical or active biological agent to prevent or treat a disease (meaning any treatment of a disease in a mammal, including preventing the disease, i.e. causing the clinical symptoms of the disease not to develop; inhibiting the disease, i.e. arresting the development of clinical symptoms; and/or relieving the disease, i.e. causing the regression of clinical symptoms). Thus the activity of a pharmaceutical or active biological agent should be of therapeutic or prophylactic value.

"Secondary, tertiary and quaternary structure" as used herein are defined as follows. The active biological agents of the present invention will typically possess some degree of secondary, tertiary and/or quaternary structure, upon which the activity of the agent depends. As an illustrative, non-limiting example, proteins possess secondary, tertiary and quaternary structure. Secondary structure refers to the spatial arrangement of amino acid residues that are near one another in the linear sequence. The a-helix and the β-strand are elements of secondary structure. Tertiary structure refers to the spatial arrangement of amino acid residues that are far apart in the linear sequence and to the pattern of disulfide bonds. Proteins containing more than one polypeptide chain exhibit an additional level of structural organization. Each polypeptide chain in such a protein is called a subunit. Quaternary structure refers to the spatial arrangement of subunits and the nature of their contacts. For example hemoglobin consists of two α and two β chains. It is well known that protein function arises from its conformation or three dimensional arrangement of atoms (a stretched out polypeptide chain is devoid of activity). Thus one aspect of the present invention is to manipulate active biological agents, while being careful to maintain their conformation, so as not to lose their therapeutic activity.

"Polymer" as used herein, refers to a series of repeating monomeric units that have been crosslinked or polymerized. Any suitable polymer can be used to carry out the present invention. It is possible that the polymers of the invention may also comprise two, three, four or more different polymers. In some embodiments, of the invention only one polymer is used. In some preferred embodiments a combination of two polymers are used. Combinations of polymers can be in varying ratios, to provide coatings with differing properties. Those of skill in the art of polymer chemistry will be familiar with the different properties of polymeric compounds. Examples ofploymers that may be used in the present invention include, but are not limited to polycarboxylic acids, cellulosic polymers, proteins, polypeptides, polyvinylpyrrolidone, maleic anhydride polymers, polyamides, polyvinyl alcohols, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters, polyurethanes, polystyrenes, copolymers, silicones, polyorthoesters, polyanhydrides, copolymers ofvinyl monomers, polycarbonates, polyethylenes, polypropylenes, polylactic acids, polyglycolic acids, polycaprolactones, polyhydroxybutyrate valerates, polyacrylamides, polyethers, polyurethane dispersions, polyacrylates, acrylic latex dispersions, polyacrylic acid, mixtures and copolymers thereof. The polymers of the present invention may be natural or synthetic in origin, including gelatin, chitosan, dextrin, cyclodextrin, Poly(urethanes), Poly(siloxanes) or silicones, Poly(acrylates) such as poly(methyl methacrylate), poly(butyl methacrylate), and Poly(2-hydroxy ethyl methacrylate), Poly( vinyl alcohol) Poly( ole fins) such as poly( ethylene), poly( isoprene), halogenated polymers such as Poly(tetrafluoroethylene) - and derivatives and copolymers such as those commonly sold as Teflon^® products, Poly(vinylidine fluoride), Poly( vinyl acetate), Poly( vinyl pyrrolidone ),. Poly( acrylic acid), Polyacrylamide, Poly( ethylene-co-vinyl acetate), Poly( ethylene glycol), Poly(propylene glycol), Poly( methacrylic acid); etc. Suitable polymers also include absorbable and/or resorbable polymers including the following, combinations, copolymers and derivatives of the following: Polylactides (PLA), Polyglycolides (PGA), Poly(lactide-co-glycolides) (PLGA), Polyanhydrides, Polyorthoesters, Poly(N -(2-hydroxypropyl) methacrylamide), Poly(laspartamide), etc.

"Therapeutically desirable morphology" as used herein refers to the gross form and structure of the pharmaceutical agent, once deposited on the substrate, so as to provide for optimal conditions of ex vivo storage, in vivo preservation and/or in vivo release. Such optimal conditions may include, but are not limited to increased shelf life, increased in vivo stability, good biocompatibility, good bioavailability or modified release rates. Typically, for the present invention, the desired morphology of a pharmaceutical agent is crystalline Preferably at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the pharmaceutical agent is in crystalline form.

"Stabilizing agent" as used herein refers to any substance that maintains or enhances the stability of the biological agent. Ideally these stabilizing agents are classified as Generally Regarded As Safe (GRAS) materials by the US Food and Drug Administration (FDA). Examples of stabilizing agents include, but are not limited to carrier proteins, such as albumin, gelatin, metals or inorganic salts. Pharmaceutically acceptable excipient that may be present can further be found in the relevant literature, for example in the Handbook of Pharmaceutical Additives: An International Guide to More Than 6000 Products by Trade Name, Chemical, Function, and Manufacturer; Michael and Irene Ash (Eds.); Gower Publishing Ltd.; Aldershot, Hampshire, England, 1995.

"Compressed fluid" as used herein refers to a fluid of appreciable density (e.g., >0.2 glee) that is a gas at standard temperature and pressure. "Supercritical fluid", "near-critical fluid", "near-supercritical fluid", "critical fluid", "densified fluid" or "densified gas" as used herein refers to a compressed fluid under conditions wherein the temperature is at least 80% of the critical temperature of the fluid and the pressure is at least 50% of the critical pressure of the fluid.

Examples of substances that demonstrate supercritical or near critical behavior suitable for the present invention include, but are not limited to carbon dioxide, isobutylene, ammonia, water, methanol, ethanol, ethane, propane, butane, pentane, dimethyl ether, xenon, sulfur hexafluoride, halogenated and partially halogenated materials such as chlorofluorocarbons, hydrochlorofluorocarbons, hydrofluorocarbons, perfluorocarbons (such as perfluoromethane and perfuoropropane, chloroform, trichloro-fluoromethane, dichloro-difluoromethane, dichlorotetrafluoroethane) and mixtures thereof.

"Sintering" as used herein refers to the process by which parts of the matrix or the entire polymer matrix becomes continuous (e.g., formation of a continuous polymer film). As discussed below, the sintering process is controlled to produce a fully conformal continuous matrix (complete sintering) or to produce regions or domains of continuous coating while producing voids (discontinuities) in the matrix. As well, the sintering process is controlled such that some phase separation is obtained between polymer different polymers (e.g., polymers A and B) and/or to produce phase separation between discrete polymer particles. Through the sintering process, the adhesions properties of the coating are improved to reduce flaking of detachment of the coating from the substrate during manipulation in use. As described below, in some embodiments, the sintering process is controlled to provide incomplete sintering of the polymer matrix. In embodiments involving incomplete sintering, a polymer matrix is formed with continuous domains, and voids, gaps, cavities, pores, channels or, interstices that provide space for sequestering a therapeutic agent which is released under controlled conditions. Depending on the nature of the polymer, the size of polymer particles and/or other polymer properties, a compressed gas, a densified gas, a near critical fluid or a super-critical fluid may be employed. In one example, carbon dioxide is used to treat a substrate that has been coated with a polymer and a drug, using dry powder and RESS electrostatic coating processes. In another example, isobutylene is employed in the sintering process. In other examples a mixture of carbon dioxide and isobutylene is employed.

When an amorphous material is heated to a temperature above its glass transition temperature, or when a crystalline material is heated to a temperature above a phase transition temperature, the molecules comprising the material are more mobile, which in turn means that they are more active and thus more prone to reactions such as oxidation. However, when an amorphous material is maintained at a temperature below its glass transition temperature, its molecules are substantially immobilized and thus less prone to reactions. Likewise, when a crystalline material is maintained at a temperature below its phase transition temperature, its molecules are substantially immobilized and thus less prone to reactions. Accordingly, processing drug components at mild conditions, such as the deposition and sintering conditions described herein, minimizes cross-reactions and degradation of the drug component. One type of reaction that is minimized by the processes of the invention relates to the ability to avoid conventional solvents which in turn minimizes autoxidation of drug, whether in amorphous, semi-crystalline, or crystalline form, by reducing exposure thereof to free radicals, residual solvents and autoxidation initiators.

"Rapid Expansion of Supercritical Solutions" or "RESS" as used herein involves the dissolution of a polymer into a compressed fluid, typically a supercritical fluid, followed by rapid expansion into a chamber at lower pressure, typically near atmospheric conditions. The rapid expansion of the supercritical fluid solution through a small opening, with its accompanying decrease in density, reduces the dissolution capacity of the fluid and results in the nucleation and growth of polymer particles. The atmosphere of the chamber is maintained in an electrically neutral state by maintaining an isolating "cloud" of gas in the chamber. Carbon dioxide or other appropriate gas is employed to prevent electrical charge is transferred from the substrate to the surrounding environment.

"Bulk properties" properties of a coating including a pharmaceutical or a biological agent that can be enhanced through the methods of the invention include for example: adhesion, smoothness, conformality, thickness, and compositional mixing.

The present invention provides several advantages which overcome or attenuate the limitations of current technology for bioabsorbable stents. Fro example, an inherent limitation of conventional bioabsorbable polymeric materials relates to the difficulty in forming to a strong, flexible, deformable (e.g. balloon deployable) stent with low profile. The polymers generally lack the strength of high performance metals. The present invention overcomes these limitations by creating a laminate structure in the essentially polymeric stent. Without wishing to be bound by any specific theory or analogy, the increased strength provided by the stents of the invention can be understood by comparing the strength of plywood vs. the strength of a thin sheet of wood.

EXAMPLES

The following examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof. The following examples are provided to illustrate selected embodiments. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof. Thus, the examples provided below, while illustrated with a particular medical device or active agent, are applicable to the range of medical devices and active agents described herein.

POLYMER STENT Reference-Example 1 - Gel Spun Polymer Fibers

Spinning is manufacturing process for creating polymer fibers. It is a specialized form of extrusion that uses a spinneret to form multiple continuous filaments. First, the polymer being spun must be converted into a fluid state. If the polymer is a thermoplastic then it is just melted, if not then it may be dissolved in a solvent or chemically treated to form soluble or thermoplastic derivatives.

In this non-limiting example, the polymer material for the bioabsorbable stent is formed by gel spinning, also known as dry-wet spinning. The polymer is in a "gel" state, only partially liquid, which keeps the polymer chains somewhat bound together. These bonds produce strong inter-chain forces in the fiber, which increase its tensile strength. The polymer chains within the fibers also have a large degree of orientation, which increases strength.

The fluid polymer is then forced through the spinneret to form polymer filaments. The polymer filaments first pass through air and are cooled further in a liquid bath. This produces strong inter-chain forces in the resulting filaments that can significantly increase the tensile strength of the fibers. In addition, at least a portion of the the polymer chains are aligned along the fiber axis by the shear forces during extrusion, which further enhances strength.

Reference-Example 2- Bioabsorbable Stent Formation

In this non-limiting example, the tubular scaffold of the present disclosure is made by forming a continuous wave form that includes a plurality of struts and a plurality of crowns. Each crown is a curved portion or turn within the wave form that connects adjacent struts to define the continuous wave form. In this example, the struts are substantially straight portions of the wave form 12. In other examples, the struts 18 are slightly bent or have other shapes, such as a sinusoidal wave, for example. The wave form may be formed by a single polymer fiber or filament or a plurality of interconnected polymer fibers or filaments.

The tubular scaffold also includes a plurality of connections that are configured to connect selected crowns of adjacent turns. In this non-limiting example, the connections are be created by fusing the selected crowns together. As used herein, "fusing" is defined as heating the target portions of materials to be fused together, with or without adding any additional material, to a level where the material in the target portions flow together, intermix with one another, and form a fusion when the materials cool down to, for example, room temperature.

Reference-Example 3 - Radial Strength Testing

This test is conducted to determine and graphically represent the change in stent internal diameter as a function of circumferential pressure and to determine the pressure at which deformation is no longer completely reversible for the disclosed stent. Fifteen (15) 3.0mm and fifteen (15) 4.0mm stents are subjected to all stent-manufacturing procedures. The stents are deployed to nominal pressure and removed from the delivery system. The stents are placed into a sleeve approximately 1 mm larger than the stent diameter. A vacuum is then applied and outer diameter measurements taken at various pressures. All samples should maintain a minimum of at least 50 percent of the nominal stent diameter after a 50mm Hg pressure is applied.

Reference-Example 4 - Stent Recoil Testing

This test is conducted to quantify the amount of elastic recoil. Fifteen (15) stent delivery systems of each length and diameter are subjected to all manufacturing and sterilization procedures. The stent delivery system is inflated to nominal pressure (e.g. 9ATM) and the stent is removed allowing for recoil to occur. The inner diameter at each end of the stent is recorded. Recoil is calculated subtracting the recoiled stent inner diameter from the pre-recoil inner diameter. Average recoil may ranged from 0.00508 to 0.01016 cm (0.002 to 0.004 inches).

Reference-Example 5 - Stent Expansion Testing

This test is conducted to determine if the plastic deformation experienced by the stent when expanded from the compressed profile to the final maximum deployed diameter can produce crack initiation for the disclosed stent. Fifteen (15) samples from each length and diameter are deployed to their largest possible diameters by inflating each delivery system to balloon failure. Each stent is examined at 45X magnification for potential cracks.

Reference-Example 6- Maximum Pressure (burst test) Testing

This test is conducted to demonstrate that the delivery system (with mounted stent) will not experience balloon, shaft, proximal adaptation or proximal/ distal seal loss of integrity at or below the pressure required to expand the stent to its labeled diameter. Stent delivery systems that had been subjected to all manufacturing and sterilization procedures are pressurized to 620.528 kPa (90 psi) with pressure held for 15 seconds and released for 3 seconds. The cycle is then repeated, increasing inflation pressure by 103.421 kPa (15 psi) each cycle until failure.

Reference-Example 7 - Analysis of the Strut Thickness Scanning Electron Microscopy (SEM)

A sample coated stent described herein is obtained. Thickness of the device can be assessed using this analytical technique. The thickness of multiple struts were taken to ensure reproducibility and to characterize the coating and stent. The thickness of the coating was observed by SEM using a Hitachi S-4800 with an accelerating voltage of 800V. Various magnifications are used. SEM can provide top down and cross-section images at various magnifications.

Nano X-Ray Computer Tomography

Another technique that may be used to view the physical structure of a device in 3-D is Nano Xray Computer Tomography (e.g. such as made by SkyScan).

Reference-Example 8 - Determination of the Bioabsorbability of a Device

Techniques presented with respect to showing Bioabsorbability of a polymer coating may be used to additionally and/or alternatively show the bioabsorbability of a device, for example, by GPC InVivo testing, HPLC In-Vivo Testing, GPC In-Vitro testing, HPLC In-Vitro Testing, SEM-FIB Testing, Raman Spectroscopy, SEM, and XPS as described herein with variations and adjustments which would be obvious to those skilled in the art. Another technique to view the physical structure of a device in 3-D is Nano X-Ray Computer Tomography (e.g. such as made by SkyScan), which could be used in an elution test and/or bioabsorbability test, as described herein to show the physical structure of the coating remaining on stents at each time point, as compared to a scan prior to elution/bioabsorbtion ..

DRUG ELUTION POLYMER STENT Reference-Example 11 - Determination of an Elution Profile In Vitro

In one method, a stent described herein is obtained. The elution profile is determined as follows: stents are placed in 16 mL test tubes and 15 mL of 10 mM PBS (pH 7.4) is pipetted on top. The tubes are capped and incubated at 37 C with end-over-end rotation at 8 rpm. Solutions are then collected at the designated time points (e.g. 1d, 7d, 14d, 21d, and 28d) (e.g. 1 week, 2 weeks, and 10 weeks) and replenished with fresh 1.5 ml solutions at each time point to prevent saturation. One mL of DCM is added to the collected sample of buffer and the tubes are capped and shaken for one minute and then centrifuged at 200 times G for 2 minutes. The supernatant is discarded and the DCM phase is evaporated to dryness under gentle heat (40 degree C) and nitrogen gas. The dried DCM is reconstituted in 1 mL of 60:40 acetonitrile: water (v/v) and analyzed by HPLC. HPLC analysis is performed using Waters HPLC system (mobile phase 58:37:5 acetonitrile:water:methanol1 mL/min, 20 uL injection, C18 Novapak Waters column with detection at 232 nm).

In another method, the in vitro pharmaceutical agent elution profile is determined by a procedure comprising contacting the device with an elution media comprising ethanol (5%) wherein the pH of the media is about 7.4 and wherein the device is contacted with the elution media at a temperature of about 37.degree. C. The elution media containing the device is optionally agitating the elution media during the contacting step. The device is removed (and/or the elution media is removed) at least at designated time points (e.g. 1 h, 3 h, 5 h, 7 h, 1d, and daily up to 28d) (e.g. 1 week, 2 weeks, and 10 weeks). The elution media is then assayed using a UV-Vis for determination of the pharmaceutical agent content. The elution media is replaced at each time point with fresh elution media to avoid saturation of the elution media. Calibration standards containing known amounts of drug were also held in elution media for the same durations as the samples and used at each time point to determine the amount of drug eluted at that time (in absolute amount and as a cumulative amount eluted).

In another method, the in vitro pharmaceutical agent elution profile is determined by a procedure comprising contacting the device with an elution media comprising ethanol (20%) and phosphate buffered saline (80%) wherein the pH of the media is about 7.4 and wherein the device is contacted with the elution media at a temperature of about 37.degree. C. The elution media containing the device is optionally agitating the elution media during the contacting step. The device is removed (and/or the elution media is removed) at least at designated time points (e.g. 1 h, 3 h, 5 h, 7 h, 1d, and daily up to 28d) (e.g. 1 week, 2 weeks, and 10 weeks). The elution media is replaced periodically (at least at each time point, and/or daily between later time points) to prevent saturation; the collected media are pooled together for each time point. The elution media is then assayed for determination of the pharmaceutical agent content using HPLC. The elution media is replaced at each time point with fresh elution media to avoid saturation of the elution media. Calibration standards containing known amounts of drug are also held in elution media for the same durations as the samples and used at each time point to determine the amount of drug eluted at that time (in absolute amount and as a cumulative amount eluted). Where the elution method changes the drug over time, resulting in multiple peaks present for the drug when tested, the use of these calibration standards will also show this change, and allows for adding all the peaks to give the amount of drug eluted at that time period (in absolute amount and as a cumulative amount eluted).

To obtain an accelerated in-vitro elution profile, an accelerated elution buffer comprising 18% v/v of a stock solution of 0.067 mol/L KH₂P0₄ and 82% v/v of a stock solution of 0.067 mol/L Na2HP04 with a pH of 7.4 is used. Stents described herein are expanded and then placed in 1.5 ml solution of this accelerated elution in a 70 degree Celsius bath with rotation at 70 rpm The solutions are then collected at the following time points: 0 min., 15 min., 30 min., 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 20 hr, 24 hr, 30 hr, 36 hr and 48 hr. Fresh accelerated elution buffer are added periodically at least at each time point to replace the incubated buffers that are collected and saved in order to prevent saturation. For time points where multiple elution media are used (refreshed between time points), the multiple collected solutions are pooled together for liquid extraction by dichloromethane. Dichloromethane extraction and HPLC analysis is performed in the manner described previously.

In Vivo

Rabbit in vivo models as described above are euthanized at multiple time points. Stents are explanted from the rabbits. The explanted stents are placed in 16 mL test tubes and 15 mL of 10 mM PBS (pH 7.4) is pipette on top. One mL of DCM is added to the buffer and the tubes are capped and shaken for one minute and then centrifuged at 200.times.G for 2 minutes. The supernatant is discarded and the DCM phase is evaporated to dryness under gentle heat (40.degree. C.) and nitrogen gas. The dried DCM is reconstituted in 1 mL of 60:40 acetonitrile: water (v/v) and analyzed by HPLC. HPLC analysis is performed using Waters HPLC system (mobile phase 58:37:5 acetonitrile: water: methanol 1mL/min, 20 uL injection, C18 Novapak Waters column with detection at 232 nm).

Reference-Example 12 - Crystallinity of Drug

The presence and or quantification of the active agent crystallinity can be determined from a number of characterization methods known in the art, but not limited to, XRPD, vibrational spectroscopy (FTIR, NIR, Raman), polarized optical microscopy, calorimetry, thermal analysis and solid-state NMR.

X-Ray Diffraction to Determine the Presence and/or Quantification of Active Agent Crystallinity

Active agent and polymer coated proxy substrates are prepared using 316L stainless steel coupons for X-ray powder diffraction (XRPD) measurements to determine the presence of crystallinity of the active agent. The coating on the coupons is equivalent to the coating on the stents described herein. Coupons of other materials described herein, such as cobalt-chromium alloys, may be similarly prepared and tested. Likewise, substrates such as stents, or other medical devices described herein may be prepared and tested. Where a coated stent is tested, the stent may be cut lengthwise and opened to lay flat in a sample holder.

For example XRPD analyses are performed using an X-ray powder diffractometer (for example, a Bruker D8 Advance X-ray diffractometer) using Cu Kα radiation. Diffractograms are typically collected between 2 and 40 degrees 2 theta. Where required low background XRPD sample holders are employed to minimize background noise.

The diffractograms of the deposited active agent are compared with diffractograms of known crystallized active agents, for example micronized crystalline sirolimus in powder form. XRPD patterns of crystalline forms show strong diffraction peaks whereas amorphous show diffuse and non-distinct patterns. Crystallinity is shown in arbitrary Intensity units.

A related analytical technique which may also be used to provide crystallinity detection is wide angle scattering of radiation (e.g.; Wide Anle X-ray Scattering or WAXS), for example, as described in F. Unger, et al., "Poly (ethylene carbonate): A thermoelastic and biodegradable biomaterial for drug eluting stent coatings?" Journal of Controlled Release, Volume 117, Issue 3, 312-321 (2007) for which the technique and variations of the technique specific to a particular sample would be obvious to one of skill in the art.

Raman Spectroscopy

Raman spectroscopy, a vibrational spectroscopy technique, can be useful, for example, in chemical identification, characterization of molecular structures, effects of bonding, identification of solid state form, environment and stress on a sample. Raman spectra can be collected from a very small volume ( < 1 µm³); these spectra allow the identification of species present in that volume. Spatially resolved chemical information, by mapping or imaging, terms often used interchangeably, can be achieved by Raman microscopy.

Raman spectroscopy and other analytical techniques such as described in Balss, et al., "Quantitative spatial distribution of sirolimus and polymers in drug-eluting stents using confocal Raman microscopy" J. of Biomedical Materials Research Part A, 258-270 (2007), and/or described in Belu et al., "Three-Dimensional Compositional Analysis of Drug Eluting Stent Coatings Using Cluster Secondary Ion Mass Spectroscopy" Anal. Chem 80: 624-632 (2008) may be used.

For example, to test a sample using Raman microscopy and in particular confocal Raman microscopy, it is understood that to get appropriate Raman high resolution spectra sufficient acquisition time, laser power, laser wavelength, sample step size and microscope objective need to be optimized. For example a sample (a coated stent) is prepared as described herein. Alternatively, a coated coupon could be tested in this method. Maps are taken on the coating using Raman microscopy. A WITec CRM 200 scanning confocal Raman microscope using a Nd:YAG laser at 532 nm is applied in the Raman imaging mode. The laser light is focused upon the sample using a 100x dry objective (numerical aperture 0.90), and the finely focused laser spot is scanned into the sample. As the laser scans the sample, over each 0.33 micron interval a Raman spectrum with high signal to noise is collected using 0.3 seconds of integration time. Each confocal cross-sectional image of the coatings displays a region 70 µm wide by 10 µm deep, and results from the gathering of 6300 spectra with a total imaging time of 32 min.

Multivariate analysis using reference spectra from samples of rapamycin (amorphous and crystalline) and polymer are used to deconvolve the spectral data sets, to provide chemical maps of the distribution.

Infrared (IR) Spectroscopy for In-Vitro Testing

Infrared (IR) Spectroscopy such as FTIR and ATR-IR are well utilized techniques that can be applied to show, for example, the quantitative drug content, the distribution of the drug in the sample coating, the quantitative polymer content in the coating, and the distribution of polymer in the coating. Infrared (IR) Spectroscopy such as FTIR and ATR-IR can similarly be used to show, for example, drug crystallinity. The following table lists the typical IR materials for various applications. These IR materials are used for IR windows, diluents or ATR crystals.

MATERIAL	NACL	KBR	CSI	AGCL	GE	ZNSE	DIAMOND
Transmission range (cm-1)	40,000	40,000	40,000	25,000	5,500	20,000	40,000
Transmission range (cm-1)	∼625	∼400	∼200	∼360	∼625	∼454	∼2,500 & 1667-33
Water sol (g/100g, 25C)	35.7	53.5	44.4	Insol.	Insol.	Insol.	Insol.
Attacking materials	Wet Solvents	Wet Solvents	Wet Solvents	Ammonium Salts	H2S04, Aqua regin	Acids, Strong alkalies, chlorinated solvents	K2Cr20s, conc. H2S04

In one test, a coupon of crystalline ZnSe is coated by the processes described herein, creating a PDPDP (Polymer, Drug, Polymer, Drug, Polymer) layered coating that is about 10 microns thick. The coated coupon is analyzed using FTIR. The resulting spectrum shows crystalline drug as determined by comparison to the spectrum obtained for the crystalline form of a drug standard (i.e. a reference spectrum).

Differential Scanning Calorimetry (DSC)

DSC can provide qualitative evidence of the crystallinity of the drug (e.g. rapamycin) using standard DSC techniques obvious to one of skilled in the art. Crystalline melt can be shown using this analytical method (e.g. rapamycin crystalline melting - at about 185 °C to 200 °C, and having a heat of fusion at or about 46.8 J/ g). The heat of fusion decreases with the percent crystallinity. Thus, the degree of crystallinity could be determined relative to a pure sample, or versus a calibration curve created from a sample of amorphous drug spiked and tested by DSC with known amounts of crystalline drug. Presence (at least) of crystalline drug on a stent could be measured by removing (scraping or stripping) some drug from the stent and testing the coating using the DSC equipment for determining the melting temperature and the heat of fusion of the sample as compared to a known standard and/or standard curve.

Confocal Raman Microscopy

Confocal Raman Microscopy can provide nondestructive depth analysis and allows coating specific Raman spectral features to be obtained (Bugay et al., "Raman Analysis of Pharmaceuticals," in "Applications of Vibrational Spectroscopy in Pharmaceutical Research and Development, "Ed. Pivonka, D. E., Chalmers, J. M, Griffiths, P.R. (2007) Wiley and Sons ). In confocal Raman microscopy an aperture is place in a focal place of the collected beam. This limitation defines a shallow portion of the depth of field and thereby provides definition of the z-axis spatial resolution for data collection. By adjusting the aperture and moving the focus within the sample, the sampling position within the sample moves. Moving the sample focus from the top surface, deeper into the specimen facilitates nondestructive depth analysis.

Reference-Example 13- Coating Uniformity

The ability to uniformly coat devices, e.g., pre- and post-expansion stents, and balloons, with controlled composition and thickness using electrostatic capture in a rapid expansion of supercritical solution (RESS) experimental series has been demonstrated.

Scanning Electron Microscopy (SEM)

Devices are observed by SEM using a Hitachi S-4800 with an accelerating voltage of 800V. Various magnifications are used to evaluate the integrity, especially at high strain regions. SEM can provide top-down and cross-section images at various magnifications. Coating uniformity and thickness can also be assessed using this analytical technique.

Pre- and post-inflation balloons, for example, may be observed by SEM using a Hitachi S-4800 with an accelerating voltage of 800V. Various magnifications may be used to evaluate the integrity of the layers, and or of the coating.

Scanning Electron Microscopy (SEM) with Focused Ion Beam (FIB)

Devices as described herein, and or produced by methods described herein are visualized using SEM-FIB analysis. Alternatively, a coated coupon could be tested in this method. Focused ion beam FIB is a tool that allows precise site-specific sectioning, milling and depositing of materials. FIB can be used in conjunction with SEM, at ambient or cryo conditions, to produce in-situ sectioning followed by high-resolution imaging. Cross-sectional FIB images may be acquired, for example, at 7000x and/or at 20000x magnification. An even coating of consistent thickness is visible.

Optical Microscopy

An optical microscope may be used to create and inspect the devices and to empirically survey the coating of the substrate (e.g. coating uniformity). Nanoparticles of the drug and/or the polymer can be seen on the surfaces of the substrate using this analytical method. Following sintering, the coatings can be see using this method to view the coating conformality and for evidence of crystallinity of the drug.

Reference-Example 14- Total Drug Content on Coated Stent (Used or Unused)

Determination of the total content of the active agent in a coated substrate may be tested using techniques described herein as well as other techniques obvious to one of skill in the art, for example using GPC and HPLC techniques to extract the drug from the coated substrate and determine the total content of drug in the sample.

UV-VIS can be used to quantitatively determine the mass ofrapamycin (or another active agent) coated onto the substrates. A UV-Vis spectrum ofrapamycin can be shown and a rapamycin calibration curve can be obtained, (e.g. λ @ 277nm in ethanol). Rapamycin is then dissolved from the coated substrate in ethanol, and the drug concentration and mass calculated.

In one test, the total amount of rapamycin (or another active agent) present in units of micrograms per substrate is determined by reverse phase high performance liquid chromatography with UV detection (RP-HPLC-UV). The analysis is performed with modifications of literature-based HPLC methods for rapamycin (or the other active agent) that would be obvious to a person of skill in the art. The average drug content of samples (n= 10) from devices comprising stents and coatings as described herein, and/or methods described herein are tested.

Reference-Example 15- Stent Laser-Cut from PLLA Tube

An exemplary stent is fabricated (laser-cutting) from a PLLA polymer tube. The tube has an outer diameter of ~3mm and a wall thickness of- 150 µm. The mechanical properties of the PLLA tube (stress at yield, strain at yield, stress at break, and strain at break) are summarized in the table below.

	Stress at Yield MPa (ksi)		Strain at Yield %	Stress at Break MPa (ksi)		Strain at Break %
Radial	80	12	30	110	16	125
Axial	70	10	45	70	10	340

FIG. 1 shows the stent after laser cutting. For illustration purpose only, stent is shown in FIG. 1 on the left in its planar form, and on the right in its tubular form (viewed in the axial direction). The stent illustrated in FIG. 1 has a strut thickness of -0.004 inch (~101.6µm; "Group A and Group 1). However, other exemplary stents are similarly formed with a strut thickness of -0.005 inch(~ 127 µm; Group 5). All stents in Group A, Group 1, and Group 5 have an average wall thickness of -0.006 inch (~152-153µm). Stents in Group 1 and Group 5 are tested after crimping on a 3.0X9mm balloon delivery system. FIG. 2 show the stents as crimped on the balloon delivery system.

Reference-Example 16- Recoil Test

The stents in Group 1 and Group 5 according to Example 15 are tested for recoil at 16 ATM. The results are shown in FIG. 3.

Reference-Example 17- Foreshortening Test

The stents in Group 1 and Group 5 according to Example 15 are tested for foreshortening at 16 ATM, by measuring the decrease of length of a stent from its crimped state to its deployed state at 16 ATM. The results are shown in FIG. 4.

Reference-Example 18 - Stent Retention Test

The stents in Group 1 and Group 5 according to Example 15 are tested for stent retention by measuring stent retention force. In this test, Group 1 is further divided into a first group of stents that are track preconditioned, and a second group of stents that are not. The stent in Group 5 is not track preconditioned. The results are shown in FIG. 5.

Reference-Example 19 -Access, Track, and Retraction Test

The stents in Group 1 (5 samples) are evaluated in an ASTM glass track model for 3 cycles. All tested samples move smoothly over the guide wire and around bends in the tortuous track.

Reference-Example 20 -Radial Strength Test

The stents in Group A, Group 1, and Group 5 according to Example 15 are tested for radial strength. The results are shown in FIG. 6. In addition, the radial force necessary to reduce outer diameter by 15% after stent deployment is listed in the Table below.



1	2.73	54.33
2	2.75	57.60
3	2.75	56.48


4	2.61	29.70
5	2.67	32.85
6	2.65	40.78
7	2.66	39.63
8	2.66	33.93
9	2.72	34.80
10	2.66	31.95
11	2.41	38.02
12	2.68	32.72
13	2.65	34.70


14	2.62	47.36
15	2.72	62.10
16	2.70	60.60
17	2.71	76.82
18	2.69	69.54

Reference-Example 21 -Deployment Test

The stents in Group 1 according to Example 15 are mounted on a 3.OX9mm balloon delivery system and expanded. The results are shown in FIG. 7. All stents tested reaches nominal ID (3 mm) at about 12 ATM. The stents do not exhibit dogboning as the tested stent have outer diameters that, on average, are greater than the outer diameters of the balloon- proximal end by 0.361 mm (o=0.22); and distal end by 0.382 nnn (o=0.25). In addition, the tested balloons have an average burst pressure of 24 psi (o=2.2), which is comparable to similar metal stents.

Reference-Example 22 - Microscopic Evaluation of Deployed Stent

Exemplary stents in Group A, Group 1, and Group 5 are examined through microscopic imaging for structural integrity (cracks, deformation, etc.) after balloon expansion.

FIG. 8 illustrate one stent in Group A (Example No. 1 listed in Table above) before radial force is applied. No apparent cracking of deformation is observed.

FIG. 9 illustrate one stent in Group 1 (Example No. 5 listed in Table above) before radial force is applied. No apparent cracking of deformation is observed

FIG. 10 illustrate one stent in Group 5 (Example No. 18 listed in Table above) before radial force is applied. No apparent cracking of deformation is observed.

It is intended that the following claims define the scope of the invention.

Claims

A biomedical implant, comprising:
a tubular scaffold comprising a plurality of interconnected bioabsorbable polymer struts, the interconnected polymer struts defining a plurality of deformable cells,

wherein the tubular scaffold includes polymer chains that are circumferentially aligned along a center axis of the tubular scaffold, so that the tubular scaffold has an average axial elastic modulus along a center axis of the tubular scaffold and an average circumferential elastic modulus orthogonal to the center axis of the tubular scaffold, the average circumferential elastic modulus being greater than the average axial elastic modulus,

a pharmaceutical agent incorporated to the tubular scaffold,

wherein at least a portion of the tubular scaffold is covered with a coating comprising the pharmaceutical agent which is a macrolide immunosuppressant in crystalline form and a bioabsorbable coating polymer,

wherein the coating process involves the dry powder spraying of the pharmaceutical agent and of the polymer that is also dry powder sprayed, whereby the spraying of the agent and

the polymer is sequential or simultaneous, and

wherein the polymer struts have an average thickness of no more than 120 µm.
The biomedical implant of claim 1, wherein the tubular scaffold maintains at least 50% of its nominal luminal cross sectional area under a pressure load of 6.67 kPa (50 mmHg).
The biomedical implant of claim 1, wherein the polymer struts have an average strut thickness of 100 µm to 103 µm.
The biomedical implant of claim 1, wherein the tubular scaffold has an average wall thickness of average wall thickness of from 80 µm to 180 µm.
The biomedical implant of claim 1, wherein the polymer struts have an average deformation angle of at least 60 degrees or at least 45 degrees.
The biomedical implant of claim 1, wherein the polymer struts comprise a polymer material selected from the group consisting of polycarboxylic acids, cellulosic polymers, proteins, polypeptides, polyvinylpyrrolidone, maleic anhydride polymers, polyamides, polyvinyl alcohols, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters, aliphatic polyesters, polyurethanes, polystyrenes, silicones, silicone containing polymers, polyalkyl siloxanes, polyorthoesters, polyanhydrides, polycarbonates, polyethylenes, polypropylenes, polylactic acids, polylactides, polyglycolic acids, polyglycolides, polylactide-co-glycolides, polycaprolactones, poly(e-caprolactone)s, polyhydroxybutyrate valerates, polyacrylamides, polyethers, polyurethane dispersions, polyacrylates, acrylic latex dispersions, polyacrylic acid, polyalkyl methacrylates, polyalkylene-co-vinyl acetates, polyalkylenes, aliphatic polycarbonates, polyhydroxyalkanoates, polytetrahalooalkylenes, poly(phosphasones), and mixtures, combinations, and copolymers thereof.
The biomedical implant of claim 1, wherein the macrolide immunosuppressant is rapamycin, a prodrug, a hydrate, an ester, a salt, or a polymorph thereof.
The biomedical implant of claim 1, wherein the biomedical implant is one of vascular stent, coronary artery stent, and peripheral artery stent.
The biomedical implant of claim 1, wherein the biomedical implant is a nonvascular stent selected from the group consisting of esophageal stent, biliary stent, duodenal stent, colonic stent, and pancreatic stent.